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Abstract  
Exonuclease I (ExoI) from Escherichia coli is a monomeric enzyme that 
processively degrades single stranded DNA in the 3′ to 5′ direction and has been 
implicated in DNA recombination and repair. It functions in numerous genome 
maintenance pathways, with particularly well defined roles in methyl-directed mismatch 
repair (MMR). The Escherichia coli MMR pathway can be reconstituted in vitro with the 
activities of eight proteins (8). MutS, MutL and MutH are involved in initiation of repair 
including mismatch recognition and generation of a nick at a nearby GATC sequence (53, 
54, 55, 56). The hemimethylated state of GATC sequences immediately following 
replication serves as a signal to direct repair to the nascent strand of the DNA duplex (57, 
58). DNA helicase II and one of several exonucleases (Exonucleas I, Exonuclease VII 
and RecJ) are required to excise the error-containing DNA strand beginning at the nicked 
GATC site (34, 35). Restoration of the correct DNA sequence by repair synthesis 
involves DNA polymerase III holoenzyme and SSB, and the final nick is sealed by DNA 
ligase (34). To identify interactions with ExoI involved in MMR repair system, we used 
the yeast two-hybrid system with ExoI as bait. By screening an E.coli genomic library, E. 
coli DNA helicase II (UvrD) was identified as a potential interacting protein. UvrD has 
been shown to be required for DNA excision repair, methyl-directed mismatch repair and 
has some undefined, role in DNA replication and recombination. In this report, in vitro 
 iv 
experiments confirm that UvrD and ExoI make a direct physical interaction that may be 
required for function of the methyl-directed mismatch repair.  
Werner Syndrome is a rare autosomal recessive disease characterized by a 
premature aging phenotype, genomic instability and a dramatically increased incidence of 
cancer and heart disease.  Mutations in a single gene encoding a 1,432 amino-acid 
helicase/exonuclease (hWRN) have been shown to be responsible for the development of 
this disease.  We have cloned, over-expressed and purified a minimal, 171-amino acid 
fragment of hWRN that functions as an exonuclease.   This fragment, encompassing 
residues 70-240 of hWRN (hWRN-N70-240), exhibits the same level of 3’-5’ exonuclease 
activity as the previously described exonuclease fragment encompassing residues 1-333 
of the full-length protein.  The fragment also contains a 5’-protruding DNA strand 
endonuclease activity at a single-strand/double-strand DNA junction and within single-
stranded DNA, as well as a 3’-5’ exonuclease activity on single-stranded DNA. We find 
hWRN-N70-240 is in a trimer-hexamer equilibrium in the absence of DNA when examined 
by gel filtration chromatography and atomic force microscopy (AFM). Upon the addition 
of DNA substrate, hWRN-N70-240 forms a hexamer and interacts with the recessed 3’-end 
of the DNA. Moreover, we find that the interaction of hWRN-N70-240 with the replication 
protein PCNA also causes this minimal, 171-amino acid exonuclease region to form a 
hexamer.  Thus, the active form of this minimal exonuclease fragment of human WRN 
appears to be a hexamer.  The implications the results presented here have on our 
understanding of hWRN’s roles in DNA replication and repair are discussed. 
 v 
The pregnane X receptor (PXR) is a nuclear xenobiotic receptor which acts as a 
molecular sentry that detects potentially toxic foreign chemicals and activates genes to 
initiate their breakdown and removal.  PXR fills this role by its ability to promiscuously 
bind to a diverse array of structurally distinct ligands which in turn enables it to activate a 
wide array of genes such as CYP3A, a monooxygenase involved in breaking down 
greater than 50 percent of all drugs and MDR1, a drug and xenobiotic efflux pump.  
Activation of PXR has the potentially deadly side effect of causing drug-drug 
interactions.  Crystal structures of the human PXR ligand binding domain (LBD) have 
revealed a number of unique features which could facilitate PXR’s promiscuous binding 
activity.  Chief among these is a very large and highly conformable hydrophobic ligand 
binding cavity.  The overall shapes of the ligand binding cavities of hPXR-LBD without 
ligand and bound to endogenous compound 17β estradiol and the LXR ligand T1317 are 
distinct. Several structural features of PXR contribute to the plasticity of its binding 
cavity including an extended beta-sheet region and two novel helices.  One of the novel 
helices and the extended beta-sheet frames the critical second unique helix.  This highly 
flexible helix, called the pseudo-helix due to its variance from the canonical alpha-helical 
conformation, adopts distinct orientations in every structure solved and plays the single 
most important role in adapting the shape of the binding cavity to fit different ligand 
orientations.   The accumulating structural data provides important insights into how 
PXR detects xenobiotics and endobiotics and may prove useful in structure based drug 
design. 
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Abstract 
 Exonuclease I (ExoI) from Escherichia coli is a monomeric enzyme that 
processively degrades single stranded DNA in the 3′ to 5′ direction and has been 
implicated in DNA recombination and repair. It functions in numerous genome 
maintenance pathways, with particularly well defined roles in methyl-directed mismatch 
repair (MMR). The Escherichia coli MMR pathway can be reconstituted in vitro with 
the activities of eight proteins (8). MutS, MutL and MutH are involved in initiation of 
repair including mismatch recognition and generation of a nick at a nearby GATC 
sequence (53, 54, 55, 56). The hemimethylated state of GATC sequences immediately 
following replication serves as a signal to direct repair to the nascent strand of the DNA 
duplex (57, 58). DNA helicase II and one of several exonucleases (Exonucleas I, 
Exonuclease VII and RecJ) are required to excise the error-containing DNA strand 
beginning at the nicked GATC site (34, 35). Restoration of the correct DNA sequence 
by repair synthesis involves DNA polymerase III holoenzyme and SSB, and the final 
nick is sealed by DNA ligase (34). To identify interactions with ExoI involved in MMR 
repair system, we used the yeast two-hybrid system with ExoI as bait. By screening an 
E.coli genomic library, E. coli DNA helicase II (UvrD) was identified as a potential 
interacting protein. UvrD has been shown to be required for DNA excision repair, 
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methyl-directed mismatch repair and has some undefined, role in DNA replication and 
recombination. In this report, in vitro experiments confirm that UvrD and ExoI make a 
direct physical interaction that may be required for function of the methyl-directed 
mismatch repair. 
Introduction 
DNA damage accumulates in cells over time as a result of exposure to 
exogenous chemicals and physical agents (i.e., polychlorinated biphenyls, dioxin, 
cigarette smoke, asbestos, ultraviolet light, radon), as well as endogenous reactive 
metabolites including reactive oxygen and nitrogen species (ROS and NOS). Another 
source of DNA damage is errors that occur during normal DNA metabolism or aberrant 
DNA processing reactions, including DNA replication, recombination, and repair. 
Nucleotide mis-incorporation generates DNA base-base mismatches during DNA 
synthesis at variable rates, depending on many factors, including the specific DNA 
polymerases. In general, the replicative DNA polymerases have relatively high 
replication fidelity, while translesion DNA polymerases, which specifically bypass sites 
of DNA damage, have lower replication fidelity. DNA damage, if unrepaired, has the 
potential to generate mutations in somatic or germline cells, which can alter cellular 
phenotype and cause dysfunction and disease. To prevent such deleterious effects and 
safeguard the integrity of the genome, cells possess multiple mechanisms to repair DNA 
damage and thus prevent mutations. One such system is the critical pathway known as 
DNA mismatch repair (MMR). MMR corrects DNA mismatches generated during DNA 
replication, thereby preventing mutations from becoming permanent in dividing cells (1-
 4 
3). Because MMR reduces the number of replication-associated errors, defects in MMR 
increase the spontaneous mutation rate (4). Inactivation of MMR in human cells is 
associated with hereditary and sporadic human cancers (1, 3, 5), and the MMR system is 
required for cell cycle arrest and/or programmed cell death in response to certain types 
of DNA damage (6, 7). 
Thus, MMR plays a role in the DNA damage response pathway that eliminates 
severely damaged cells and prevents both mutagenesis in the short term and 
tumorigenesis in the long term. Escherichia coli MMR pathway has been extensively 
studied and is well characterized both biochemically and genetically. Thus, E. coli MMR 
is a useful and important framework for understanding eukaryotic MMR. E. coli MMR 
requires the following protein components: MutS, MutL, MutH, DNA helicase II 
(MutU/UvrD), three exonucleases (ExoI, ExoVII, and RecJ), single-stranded DNA 
binding protein (SSB), DNA polymerase III holoenzyme, and DNA ligase (8, 9). MutS, 
MutL, and MutH initiate MMR and play specialized biological roles in MMR in E. coli. 
MutS recognizes base-base mismatches and small nucleotide insertion/deletion (ID) 
mispairs, and thus MutS has been called the “mismatch recognition” protein (3). MutS 
possesses intrinsic ATPase activity. High-resolution structures of MutS bound to DNA 
have been determined by X-ray crystallography (10, 11). These structures revealed that 
MutS binds to a mismatch as a homodimer. Interestingly, the mismatch-binding site is 
comprised of sequencewise identical but structurally and functionally different domains 
from the two subunits, indicating asymmetry in the protein-DNA complex. Hence, the 
MutS homodimer acts as a virtual heterodimer when bound to a DNA mismatch. This 
characteristic is mimicked by eukaryotic MutS homologs (MSH), which function as 
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heterodimers instead of homodimers.  MMR in E. coli is ATP-dependent, and requires 
the functional MutS ATPase. MutL interacts physically with MutS, enhances mismatch 
recognition, and recruits and activates MutH. Defects in MutL completely inhibit MMR 
in E. coli. Despite the fact that a functional human MutL homolog, MutLα, possesses an 
endonuclease activity that is essential for mammalian MMR (12), no hydrolytic activity 
has been detected in MutL. However, MutL may play a role as a molecular matchmaker 
that facilitates assembly of a functional MMR complex (3, 13), because it stimulates the 
loading and the processivity of helicase II (or UvrD) at the MMR initiation site (14, 15). 
Like MutS, MutL functions as a homodimer and possesses ATPase activity (16). 
Mutations in the ATP-binding domain lead to a dominant negative mutator phenotype 
(17). MutL mutants that are defective in ATP hydrolysis but proficient in ATP binding 
can activate MutH but cannot stimulate MutH in response to a mismatch or MutS, 
suggesting that ATP hydrolysis by MutL is essential for mediating the activation of 
MutH by MutS (18). Recent studies show that MutL interacts physically with the clamp 
loader subunits of DNA polymerase III (19, 20), suggesting that MutL may promote 
binding of DNA polymerase III to MMR intermediates. These observations suggest that 
MMR is coupled with DNA replication. In E. coli, DNA is methylated at the N6 position 
of adenine in dGATC sequences. In replicating DNA, the daughter strand is transiently 
unmethylated, and it is the presence of hemimethylated dGATC sequences that 
molecularly distinguishes the newly synthesized daughter strand from the parental DNA 
strand. In MMR, hemimethylated dGATC sites determine the strand specificity of repair. 
MutH, which recognizes hemimethylated dGATC sequences, functions as a monomer 
and belongs to a family of type-II restriction endonucleases (21, 22). Upon its recruitment 
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and activation by MutS and MutL in the presence of ATP, MutH specifically incises the 
unmethylated daughter strand of hemimethylated dGATC (3, 18), and this strand-specific 
nick provides the initiation site for mismatch-provoked excision. The first step of the 
MMR pathway is binding of a MutS homodimer to the mismatch. Subsequently, a hemi-
methylated dGATC site 5′ or 3′ to the mismatch is located and cleaved by the concerted 
action of MutS, MutL, MutH, and ATP. Three models have been proposed to address 
how mismatch binding by MutS leads to cleavage of the hemimethylated dGATC site. 
The strandspecific nick generated by MutH at hemimethylated dGATC is a starting point 
for excision of the mispaired base. In the presence of MutL, helicase II (UvrD) loads at 
the nick and unwinds the duplex from the nick towards the mismatch (14), generating 
single-strand DNA, which is rapidly bound by single-stranded DNA-binding protein 
(SSB) and protected from nuclease attack (23). Depending on the position of the strand 
break relative to the mismatch, ExoI (3′→5′ exonuclease), or ExoVII or RecJ (5′→3′ 
exonuclease) excises the nicked strand from the nicked site (the dGATC site) up to and 
slightly past the mismatch. The resulting single-stranded gap undergoes repair DNA 
resynthesis and ligation by DNA polymerase III holoenzyme, SSB, and DNA ligase (3) 
(Figure 1). These early studies on E. coli MMR demonstrate three key features of this 
important pathway: first, repair is strand specific (i.e., restricted to the newly synthesized 
DNA strand); second, repair is bi-directional, proceeding 5′→3′ or 3′→5′ from the nick to 
the site of the mismatch; and third, MMR has broad substrate specificity including base-
base mismatches and small ID mispairs. All of these properties require functional MutS, 
MutL, and MutH. Because the mechanism of MMR is highly conserved throughout 
evolution, E. coli MMR is an excellent model for MMR in eukaryotic cells. 
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The main objective of this study was to better understand the mechanism of 
Methyl-directed DNA mismatch repair in E. coli. To identify interactions within eight 
proteins involved in MMR, we used the yeast two-hybrid system with Exonuclease I as 
bait. By screening an E.coli genomic library, E. coli DNA helicase II (UvrD) was 
identified as a potential interacting protein with ExoI. UvrD has been shown to be 
required for DNA excision repair, methyl-directed mismatch repair and has some 
undefined, role in DNA replication and recombination.  ExoI was originally identified as 
a suppressor of recombination in recBC mutants. However, later results suggested that 
ExoI and other single stranded DNA exonucleases participate in recombination pathways.  
In this report, in vitro experiments confirm that UvrD and exonuclease I make a direct 
physical interaction that may be required for function of the methyl-directed mismatch 
repair. 
 
Materials and methods 
 
Strains, enzymes, DNA and nucleotides 
Escherichia coli JS4 was from Bio-Rad. Escherichia coli HB101 was from New 
England Biolabs (NEB). Escherichia coli BL21 was from Novagen. Escherichia coli K-
12 was from NEB. HF7c and SFY526, and plasmids pGAD424 and pGBT9 were from 
the Matchmaker two-hybrid system (Clontech). The primer 5’-
TTCGATGATGAAGATACC- 3’ was used to sequence the amino-terminal end of 
fusions in the pGAD series of activation domain vectors. The primer 5’-
AAGAGAGTAGTAAC3’ was used to sequence the amino-terminal end of fusions in the 
pGBD series of DNA binding domain vectors. The 3’ ends of these primers are located 
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25 and 27 bp upstream of the EcoRI site, respectively. The carboxyl-terminal end of 
fusions in either pGAD, pGBD vectors were all sequenced using the same primer, 5’-
TGAAGTGAACTTGCGGGG3‘, which is located 22 bp from the Bgl II site. 
 
Construction of two hybrid expression vector 
To generate two-hybrid libraries using a set of five different restriction enzymes, 
we needed transcription activation domain vectors with a unique ClaI site in the 
polylinker. The oligonucleotide primers (1) 5’-
TGCTTTCGAAGCTCCCCHACAGGTGTCCC- 
3’ and (2) 5’-
TTAAGAATTCCCCGGGGGATCCATCGATGTCGACCTGCAGAGATC-3' were 
used to amplify a 1666-bp fragment from the vector pGAD424. Primer 1 contains a 
BstBI site in place of the ClaI restriction site in the LEU2 gene of pGAD424. Primer 2 
introduces two single-bp insertions and a ClaI site into the pGAD424 polylinker. These 
changes were incorporated into pGAD424 in two steps. First the PCR product was 
digested with BstBI/AflII and the 194bp fragment was ligated into pGAD424 digested 
with ClaI/AflII. Next the resulting plasmid and the PCR product were both digested by 
Afl II/EcoRI, AflII/SmaI, or AflII/BamHI and each -1.5-kb PCR fragment was subcloned 
into the appropriately digested vector. The ClaI site in the LEU2 gene of the resulting 
plasmids was destroyed and a new ClaI site was introduced into the polylinker. We 
verified that each plasmid is still able to rescue both a leu2 mutation in yeast and the 
leuB6 mutation in E. coli. Cloning with BamHI, SmaI, or EcoRI also incorporated zero, 
one, or two single base insertions, respectively, into the polylinker. The resulting 
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plasmids, pGAD-Cl, pGADC2, and pGAD-C3 (Figure l), contain unique ClaI sites in 
their polylinker regions, each in a different reading frame. The DNA sequence across 
each polylinker region was verified by sequencing.  
 
Preparation of E. coli genomic DNA 
Genomic DNA was prepared from E. coli K12. A 2- liter culture grown in LB 
was harvested by centrifugation at OD600 1 .6, washed once in 500 ml ddH2O, and 
resuspended in 30 ml of 1 M sorbitol, 0.1 M EDTA. Zymolyase 20T (ICN 
Pharmaceuticals) was added to 5 mg/ml and incubated 1 hr at room temperature. The 
spheroplasts were collected by centrifugation, resuspended in 40 ml lysis buffer (24), and 
split into two 50-ml Falcon tubes. Twenty milliliters PCI (pheno1:chloroform:isoamyl 
alchohol, 25:24:1) and 6 ml acid-washed glass beads (0.45-0.55 mm) were added to each 
tube, and the mixtures were vortexed at top speed for 5 min. The supernatants were 
recovered and pooled, re-extracted three times with 20 ml PCI, and precipitated with 2 
volumes ethanol. The pellet was resuspended in 20 ml 1X TE (10 mM Tris pH 8.0, 1 mM 
EDTA pH 8.0) and RNase A was added to 50 pg/ml. After 1 hr at 37 0C, the DNA was 
extracted three more times with 20 ml PCI to achieve a clear interface and was 
precipitated with 0.6 volumes of isopropanol. The pellet was resuspended in 5 ml H2O, 
and 1 m1 5 M NaCl and 6 ml l3% PEG 8000 were added. The DNA was precipitated 4 hr 
on ice and spun 10 min at 10,000 rpm in a SS34 rotor (Sorvall). The pellet was 
resuspended in 3 ml 1 X TE and the final yield was determined by spectrophotometry to 
be 2.75 mg. 
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Construction of E. coli genomic two-hybrid libraries:  
Vector DNA was prepared by digesting 15 pg each of pGAD-Cl, pGAD-C2, and 
pGAD-C3 with 40 units of ClaI for 6 hr at 370C. Digests were treated with Wizard 
Cleanup resin (Promega) and recovered in 0.1 ml 1 X TE. Each vector digest was treated 
with 2 units of calf intestinal alkaline phosphatase (CIP, Boerhinger Mannheim) for 30 
min at 370C, 2 additional units of CIP were added, and the reactions were incubated an 
additional 30 min at 55 0C. The CIP was removed by treatment with Wizard Cleanup 
resin. Each vector preparation was then incubated with 2 units T4 DNA ligase 
(Boerhinger Mannheim) at room temperature overnight, placed at 650C for 15 min, and 
run on preparative 0.7% agarose gels to separate linear monomers from circularized and 
multimeric forms. Each linear vector DNA was recovered into 0.1 ml 1X TE. Insert DNA 
was prepared by partial digestion of E. coli K12 genomic DNA with the enzymes AciI, 
MspI, HinPlI (New England Biolabs), MaeII (Boerhinger Mannheim), and TaqI 
(Promega). For each enzyme the optimal concentration for partial digestion was 
determined in units/pg of DNA, and then five preparative reactions were carried out with 
enzyme concentrations that bracketed the optimum. Each preparative digest contained 40 
pg of genomic DNA in a total volume of 0.2 ml and was incubated for 30 min at the 
recommended temperature. The reactions were stopped by the addition of 20 µ1 0.25 M 
EDTA. 
Partial digests were analyzed by Southern blotting. The 315- bp NczI/XbaI 
fragment of the genomic DNA was radioactively labeled using the random priming 
method and used as a probe (25). For each enzyme the digest that produced the most even 
distribution of partial and complete digestion products was selected and 10 pg of each 
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digest were size fractionated on 1% agarose gels. DNA from 500 to 2000 bp for MaeII 
and TaqI, 500-2500 bp for AciI, and 500-3000 bp for MsfiI and HinPlI was recovered 
into 0.1 ml 1X TE. Fifteen ligation reactions were carried out (three vectors x five 
enzyme digests). The vector:insert ratio that resulted in optimal ligation efficiency was 
empirically determined. Each ligation reaction contained 5 µl of the vector preparation, 
40 µl of the insert preparation, and 6 units of T4 DNA ligase in a total reaction volume of 
100 µl, and was incubated at room temperature for 9 hr. Ligation reactions were ethanol 
precipitated and resuspended in 25 µl ddH20. Ligations were transformed into 
ultracompetent Escherichia coli strain JS4 (Gibco-BRL) by electroporation, using a 1.8 
kV pulse, 1 mm gap cuvettes (BTX, Inc.), 20 µl of cells, and 1 µ1 of ligation mix in each 
transformation reaction. For each of the 15 vector: insert combinations, three to seven 
transformation reactions were necessary to generate sufficient numbers of transformants. 
One milliliter of SOC was added to each transformation reaction and incubated 1 hr at 37 
0C. The three to seven transformation reactions from each ligation were pooled and a 
small aliquot was plated to determine the total number of primary transformants. The 
remainder of the transformation mixes from each ligation were inoculated into 3 liters of 
T broth containing 200 pg/ml ampicillin and incubated overnight at 37 0C resulting in a 
total of 15 cultures. At OD600 1.5 (-12 hr) cultures were chilled on ice for 30 min. For 
each of the three different reading frame vectors, five cultures (corresponding to the five 
restriction enzyme digests) were pooled in appropriate quantities to produce an equal 
representation of all restriction sites in the final library. 
The resulting three pooled cultures, one representing each reading frame, 
contained- 11 liters each and were harvested by centrifugation. DNA was prepared from 
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each pellet by large scale alkaline lysis and precipitated with ethanol. The pellets were 
resuspended in 120 ml 1X TE and treated 1 hr at 370C with 10 mg RNase A. Each was 
extracted five times with 60 ml PCI and ethanol precipitated in the presence of 300 mM 
NaAc pH 7.0. Pellets were resuspended in 33 ml ddH20, and 7 ml 5 M NaCl and 40 ml 
13% PEG 8000 were added. The DNA was precipitated overnight on ice and spun down 
10 min at 10,000 rpm (Sorvall). The DNA pellets for libraries Y2HL-C1, Y2HL-C2, and 
Y2HL-C3 were resuspended in lx TE at a concentration of 1 mg/ml. 
 
Cloning uvrD and Exonuclease I 
Vent DNA polymerase was used to amplify the uvrD gene by PCR using E. coli 
K12 genomic DNA. Amplified uvrD was sequenced and cloned into the SmaI site of 
pGAD424 and pGBT9 to create in-frame translational fusions with the Gal4 
transcriptional activation domain and DNA binding domain, respectively. These 
constructs were designated pGAD424-UvrD and pGBT9-UvrD. In similar fashion, the 
Exonuclease I gene was amplified by PCR from the genome of E. coli strain DH5α and 
gene was sequenced to make sure the gene sequence is correct before directionally cloned 
into the EcoRI and BamHI sites of pGAD424 and pGBT9 to form the appropriate 
translational fusions. These constructs were designated pGAD424-ExoI and pGBT9-
ExoI.  
 
Detection of reporter gene expression 
pGBT9-ExoI and Y2HL were cotransformed into yeast HF7c cells and plated on 
complete synthetic media lacking leucine, tryptophan and histidine, and supplemented 
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with 1 mM 3-amino-1,2,4-triazole (3-AT). 3-AT was required to suppress a low level of 
HIS3 activation by the pGBT9-UvrD DNA binding domain fusion. Transformation 
efficiencies were monitored by plating small portions of transformations on complete 
synthetic media lacking only leucine and tryptophan. Transformants capable of growth in 
the absence of histidine were colony purified and DNA was extracted as described by the 
supplier (Clontech). The pGAD424-library plasmid was recovered in each case by 
transformation into E.coli HB101 and selecting for growth on minimal media lacking 
leucine as described by the supplier. Recovered pGAD424-library plasmids were re-
transformed with pGBT9-ExoI into yeast HF7c and SFY526 cells. Confirmation of an 
interaction was performed by monitoring growth of HF7c on media lacking histidine and 
the appearance of blue color in SFY526 in the presence of X-Gal at high concentration of 
3-AT (10 mM). A spectrophotometric assay for β-galactosidase activity, using the 
substrate o-nitrophenyl β-D-galacto-pyranoside (ONPG), allowed quantification of 
experimental and control interactions (26), and was performed as described (Clontech). 
 
Purification of UvrD and ExonucleaseI 
Vent DNA polymerase was used to amplify the uvrD gene by PCR using pGBT9-
UvrD as target. Amplified uvrD was cloned into modified pET28 expression vector as 
HisTev UvrD. His-6-tagged E. coli UvrD helicase is expressed in E. coli strain BL21 
(DE3). Cells were lysed in 20 mM Tris-Cl pH 7.6, 250 mM NaCl, 2 mM TCEP, 5% 
glycerol, 20 mM imidazole, with Roche EDTA free protease inhibitor cocktail tablets,  
using a microfluidizer from microfluidics coroperation. The cellular extract was clarified 
by centrifugation at 17,000 rpm for 60 min at 4 °C, before loading onto a 40ml Ni-NTA 
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column (Qiagen). After washing extensively with buffer A (20 mM Tris-Cl pH 7.6, 250 
mM NaCl, 2 mM TCEP, 5% glycerol, 20 mM imidazole) and buffer B (20 mM Tris-Cl 
pH 7.6, 250 mM NaCl, 2 mM TCEP, 5% glycerol, 40 mM imidazole), His tagged UvrD 
was eluted from the column using buffer A containing 250 mM imidazole and then 
concentrated to 17 ml, loading onto Superdex 200 (GE) pre-equilibrated with buffer D 
(20 mM Tris-Cl pH 7.6, 150 mM NaCl, 2 mM TCEP, 5% glycerol), UvrD were pooled 
and diluted 3 fold with buffer E (20 mM Tris-Cl pH 7.6, 2 mM TCEP, 5% glycerol), and 
then loading onto MonoQ (GE), protein eluted at 180 mM NaCl. Pooled fractions were 
concentrated to 20 mg/ml and quickly frozen with nitrogen beam.  
The gene encoding Exonuclease I was amplified by PCR from pGBT9-ExoI and 
ligated into the modified pET28 overexpression vector (Novagen) with a N-terminal His 
tag consisting of six histidine residues and Tev cleavage site. The protein was 
overexpressed in a fermenter (750 rev min_1, 7.1 l s_1 air) with 4 L LB broth and 0.27 
mM ampicillin. The cells were induced at an OD of 1.2 with 1 mM IPTG for 4 h at 289 K 
(225 rev min_1, 7.5 l min_1 air). The cells were harvested and resuspended in 50 mM 
Tris–HCl pH 8.0, 5 mM imidazole, 500 mM NaCl, 0.1% Triton X-100, 10% glycerol 
(+TG buffer) and sonicated for 10 min. The cell lysate was centrifuged (17 000 rev 
min_1, Beckman JA-20 rotor) for 30 min and the supernatant was applied onto a column 
of Ni–NTA agarose resin (Qiagen). The column was washed with +TG buffer and -TG 
buffer (50 mM Tris–HCl pH 8.0, 5 mM imidazole, 500 mM NaCl) until the absorbance 
was zeroed. The protein was eluted with 250 mM imidazole. Pertinent fractions were 
pooled and dialyzed overnight against buffer C (50 mM Tris-Cl pH 8.0, 500 mM NaCl, 2 
mM TCEP, 10% glycerol, 5 mM imidazole). Tev cleavage was going on overnight and 
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then the protein sample was loaded  onto Superdex 200 (GE) pre-equilibrated with buffer 
D (50 mM Tris-Cl pH 8.0, 500 mM NaCl, 2 mM TCEP, 10% glycerol), ExoI were pooled 
and dialyzed into 50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM EDTA and 1 mM 
dithiothreitol (DTT).  Finally, ExoI were concentrated to 1 mg/ml and quickly frozen 
with nitrogen beam. 
 
Pull-down assay 
HisTev-UvrD are immobilized on Ni-NTA agarose beads by incubating 1 mg of 
purified HisTev-UvrD with 1 ml Ni beads for 1 hour at 4°C, which pre-washed with 
buffer A: 20 mM Tris, pH 7.4, 250 mM NaCl and 20 mM immidazole 4 times and 
equilibrated in the same buffer A. Wash the beads four times with 20 volumes of buffer 
A to remove unbound material, resuspend in 1ml of buffer A, and store at 4°C. Incubate 1 
mg of ExoI with the immobilized HisTev-UvrD at 4°C rotating for 1 hr. Wash the beads 
four times with 20 volumes of buffer A.  The bound proteins are eluted with 250 mM 
immidazole in the same buffer and then boiled in sample buffer and visualized using 
Coomassie blue staining. BSA was used as a control. 
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Results 
Construction of improved two-hybrid vectors 
As a first step in creating improved genomic two-hybrid libraries, we needed a set 
of vectors with a unique ClaI cloning site that could be used to generate fusions to a 
transcription activation domain. The GAL4 activation domain vector pGAD424 (27) was 
chosen because of its small size, convenient polylinker sites, and efficient rescue E. coli 
1euB mutations. Site-directed PCR mutagenesis was used to make several changes in 
pGAD424. First, the endogenous ClaI site present in the LEU2 marker gene was 
destroyed. This change did not alter the amino acid sequence of LEU2, and the plasmid 
retained the ability to rescue both leu2 mutations in yeast and leuB6 mutations in E. coli. 
Second, a new ClaI site was introduced into the center of the polylinker and single base 
pairs were inserted between the EcoRI and SmaI sites and between the SmaI and BamHI 
sites of the polylinker. By incorporating either zero, one, or two of the single base pair 
insertions into the final products, we generated a set of three new activation domain 
vectors, pGAD-C1, pGAD-C2, and pGAD-C3. Each contains a unique ClaI cloning site 
in the polylinker, but differs in the translational reading frame of the polylinker sites 
(Figure 2).  
 
Construction of E. colit genomic two-hybrid libraries 
To generate a highly complex set of libraries, we sought to increase the number of 
restriction enzymes used for the partial digestion of genomic DNA. There are five 
different commercially available enzymes with 4 bp recognition sequences that produce a 
5’ overhang with the sequence 5’-CG3’: AciI , HinPlI, MaeII, MspI, and Taq1 
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(“CGenzymes”). Each is compatible for ligation with the ClaI site introduced into the 
polylinkers of the vectors described above.  Library inserts were prepared using genomic 
DNA from E. coli K12. The genomic DNA was subjected to partial digestion by each of 
the CG enzymes. Because the inclusion of as many restriction sites as possible is critical 
to the quality of the library, partial digests were examined by Southern blotting (Figure 
3). This examination was extremely important, as we found that it was impossible to 
predict the quality of the partial digest by ethidium bromide staining. Southern blotting 
results demonstrated that digests judged to be partial by ethidium bromide staining 
actually contained fragment mixes that ranged from nearly complete to nearly uncut. The 
315- bp NczI/XbaI fragment of E. coli genomic DNA was radioactively labeled using the 
random priming method and used as a probe (25). For each enzyme the digest that 
produced the most even distribution of partial and complete digestion products was 
selected and 10 pg of each digest were size fractionated on 1% agarose gels. DNA from 
500 to 2000 bp for MaeII and TaqI, 500-2500 bp for AciI, and 500-3000 bp for MsfiI and 
HinPlI was recovered into 0.1 ml 1X TE. The optimized concentration of each enzyme 
used for partial digestion is 1.8units/ug (Figure 3). After using Southern blots to select the 
best partial digest for each enzyme, we size-fractionated the selected digests by gel 
electrophoresis. The selection of small insert sizes was desirable to minimize the 
production of false positives. However, if the selected insert size is too small, many 
complete digestion products will not be represented in the library. To avoid excluding 
completely digested fragments from the library, we examined complete digestions of 
genomic DNA by ethidium bromide staining. The largest fragment size visible was 
chosen to be the maximum insert size selected for each enzyme. As a result, restriction 
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fragments from 500 bp to a maximum of 2-3 kb were included in the libraries, with the 
maximum size depending on which enzyme was used to generate a partial digest. Vector 
DNA was prepared by digesting pGAD-C1, pGAD-C2, and pGAD-C3 with ClaI and 
treating the cleaved ends with calf intestinal phosphatase to remove the 5' phosphate 
groups. Dephosphorylated vectors were then religated, and those that remained as linear 
monomers were purified by electrophoresis. This step eliminated about 90% of the 
background caused by vector self-ligation. After determining empirically that a 1:8 
vector:insert ratio provided optimal ligation efficiency, 15 ligation reactions were 
performed and each was transformed into E. coli JS4. Fifteen separate reactions were 
required to ligate each of the three different reading frame vectors to each of the five 
different partial digestions. Production of comprehensive libraries required that a large 
number of independent clones be obtained from each of the 15 ligation reactions. 
Because of the practical limitations of recovering this number of colonies from plates, 
each reaction was inoculated into liquid T broth. To minimize the problem of clone loss 
due to competition, cultures were harvested while still in the logarithmic phase of growth. 
The five cultures that represent each reading frame were then mixed together in quantities 
that would produce equal representation of each individual restriction site in the genome. 
The mixing produced three large cultures, each representing a different reading frame and 
containing a comprehensive library of genomic DNA inserts. The detailed procedures for 
E. coli genomic library construction was summarized in Figure 4.  DNA was prepared 
from each of the three libraries, which we call Y2HLC1, Y2HL-C2, and Y2HL-C3. The 
quality of the two-hybrid libraries has been examined by a variety of methods. First, a 
large number of independent clones were obtained from each of the 15 transformation 
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reactions. The quality of a library is also dependent on the percentage of library clones 
that contain an insert. DN A was prepared from 65-75 random clones from each of the 
three libraries and inserts were analyzed by digestion with the polylinker enzymes SmaI 
and PstI followed by gel electrophoresis. A total of 300 clones were analyzed; we found 
14 without inserts and an additional 13 that contained small inserts of <400 bp. Thus 96% 
of the library plasmids contained inserts, and only 5% of those inserts were not within the 
size range we had selected.  
 
The two-hybrid screen 
To identify E.coli proteins that potentially interact with ExoI, we constructed an 
E.coli genomic library in the two-hybrid vector pGAD424 as described in Materials and 
methods. ExoI, expressed as a translational fusion with the Gal4 DNA binding domain in 
pGBT9, was used as bait. Potential interactions in the yeast two-hybrid reporter strain 
HF7c were initially selected on complete synthetic media lacking histidine. HF7c 
contains a HIS3 gene under control of the GAL1 promoter which is only expressed when 
a functional Gal4 protein is reconstituted by an interaction between the activation domain 
and DNA binding domain fusion proteins. Potential interactors with ExoI in pGAD424-
library were recovered as described in Materials and methods, and the interaction was 
confirmed by re-transformation with pGBT9-ExoI into HF7c and SFY526. SFY526 
contains a lacZ reporter gene and its expression can be monitored with the color-
producing substrates X-gal and ONPG. One of library clones from Y2HL-C1 that 
maintained an interaction in HF7c and SFY526 which was dependent on the presence of 
ExoI was sequenced and subjected to a BLAST search of the E.coli genome database. It 
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was found to be 100% identical to a portion of the mismatch repair gene UvrD (Figure 5). 
Partial sequence of UvrD gene is from 705 to 2162 bp.  We totally found 10 clones from 
three libraries mainted interactions in HF7c and SFY526 which were dependent on the 
prescence of ExoI at 10 mM 3 AT. We only sequence one which still showed interaction 
at higher concentration of 3AT (30 mM). Later on we will sequence the other nine 
clones. 
 
Full length UvrD and ExoI proteins interact in the two-hybrid system 
We were interested in examining the interaction between full length ExoI and 
UvrD. To accomplish this, UvrD was cloned from the E.coli genome DNA into 
pGAD424 and pGBT9 as described in Materials and methods. The pGAD424-ExoI and 
pGBT9-UvrD clones were used to confirm the interaction with ExoI in HF7c and 
SFY526. Figure 6 shows that growth of HF7c on complete synthetic media lacking 
histidine was dependent on the presence of both ExoI and uvrD in the two-hybrid vectors. 
The absence of ExoI, uvrD or both resulted in basal levels of reporter gene expression 
and, therefore, no growth on media lacking histidine. Identical results were obtained in 
the lacZ reporter strain SFY526 with regard to b galactosidase expression. In addition, 
the interaction was observed regardless of whether UvrD existed as a fusion with the 
Gal4 activation domain or the Gal4 DNA binding domain (Figure 6).  We next examined 
the interaction between full length RecJ (One of the exonclease involved in MMR) and 
UvrD, RecJ was cloned from the E. coli genome DNA into pGAD424 and pGBT9, the 
growth of HF7c on complete synthetic media lacking histidine was dependent on the 
presence of both RecJ and uvrD in the two-hybrid vectors (Data not shown). Result 
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showed they had interactions like ExoI with UvrD. These data showed UvrD truly 
interacted with exonuclease in E. coli DNA mismatch repair. 
 
Purified ExoI is specifically retained on a UvrD affinity column 
ExoI and UvrD were over-expressed and purified as described in Materials and 
methods. Affinity chromatography was used to demonstrate a physical interaction 
between the two purified proteins. UvrD affinity column was generated using Ni-NTA 
resin. 1 mg of UvrD was coupled to a resin volume of 5 ml. 1 mg of purified ExoI or 
control protein BSA was loaded onto the column and washed and eluted with 250 mM 
immidazole as described in Materials and methods. As shown in Figure 7A, a large 
fraction of the applied ExoI bound the UvrD affinity column and was eluted from the 
column with 250 mM immidazole washes. There were some in the flowthrough and 
washes. A control protein BSA failed to bind the UvrD column and was found 
exclusively in the flow-through and wash fractions (Figure 7B). In addition, a control 
affinity column was constructed by coupling 1 mg of his tagged 11 β HSD1 to 5 ml resin. 
1 mg of ExoI was loaded onto the control column, which was treated in the same manner 
as the UvrD column. Nearly all of the loaded ExoI was present in the flow-through and 
20 mM imidazole wash fractions (data not shown), indicating that ExoI was not retained 
on the UvrD affinity column by non-specific interactions with the resin or protein. These 
results support the conclusion that a specific physical interaction exists between UvrD 
and ExoI. 
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Discussion 
E. coli exonuclease I (ExoI) functions in numerous genome maintenance 
pathways, with particularly well defined roles in methyl-directed mismatch repair (28). In 
mismatch repair, incorrect DNA base pair formation triggers cleavage of the non-
methylated (newly synthesized) DNA strand in hemimethylated DNA, loading of UvrD 
to unwind from the nick in the direction of the error, and clearance of the nonmethylated 
ssDNA through the mispaired element by ExoI or another functionally redundant 
nuclease ExoVII or RecJ (29, 30). We used the yeast two-hybrid system to search for 
interacting protein partners that might direct the involvement of ExoI in the methyl-
directed mismatch repair and nucleotide excision repair pathways. The two-hybrid screen 
revealed an interaction between ExoI and helicase II (UvrD), an essential component for 
methyl-directed mismatch repair (31, 32, 8), future studies aimed at generating point 
mutants that exhibit defective interactions with UvrD should aid identification of the 
interaction domain in ExoI.  Recently it was shown that ExoI acts on single strand DNA 
binding protein (SSB)/ssDNA substrates (33) in In vitro reconstitution of bacterial 
mismatch repair reactions. The crystal structure of E. coli ExoI  and bound form to a 
peptide comprising the SSB-Ct element complex showed that ExoI in both crystal forms 
comprises exonuclease (residues 1–201) domain, SH3-like domain (residues 202–352), 
and helical (residues 360–476) domains (Figure 8). Bounded ExoI crystals revealed 
features corresponding to the C termini from two SSB-Ct peptides associated with the 
ExoI surface. Both peptides bind at sites that are 20 Å from the active site. The first 
peptide binds between the exonuclease and SH3-like domains of ExoI and the second 
peptide binds entirely the ExoI SH3-like domain. Examination of the SSB-Ct binding site 
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in ExoI has identified surface features that could be useful for similar interaction sites on 
ExoI’s other binding partners, like UvrD. These features include a hydrophobic pocket 
with a basic residue positioned at the lip of the pocket and flanking basic residues that 
bind the conserved acidic residues of the SSB-Ct.  Interactions with SSB protein are 
likely to be important for ExoI function. It had also showed RecJ, another functionally 
redundant nuclease in DNA mismatch repair system, had direct interaction with SSB. In 
our in vivo study we also showed RecJ interact with UvrD. During processive ssDNA 
degradation, ExoI or RecJ must displace the tightly bound SSB to move ssDNA into their 
cleft, a process that could be facilitated by specific interactions between the two proteins. 
Our in vitro experiments showed that ExoI made a direct physical interaction with UvrD, 
however, the mechanism underlying ExoI-UvrD interaction has remained poorly defined. 
We are currently exploring the functional importance of the ExoI–UvrD interaction for 
methyl-directed mismatch repair. In Junghoon in Dr. Dorothy Erie lab recetly showed the 
interaction between UvrD and SSB in DNA mismatch repair. SSB may play a critical 
role in coordinating the excision repair process in living cells.  A plausible mechanism is 
that SSB interacts with UvrD and that interaction strongly stimulates helicase activity of 
UvrD at nicked DNA fragments. The interaction of SSB and UvrD induce the 
conformational change of UvrD or SSB and may then load ExoI or RecJ onto ssDNA 
sequences, the sequential timing for ExoI interact with UvrD and SSB is unknown. ExoI 
or RecJ interact with SSB tightly but with UvrD weakly. During degradation of ssDNA, 
ExoI or RecJ displace the tightly bound SSB to push ssDNA into their cleft.  Because 
UvrD unwinds exclusively in a 3’ to 5’ direction with respect to the bound DNA strand 
(37, 38), bidirectional unwinding from a nick necessitates the ability of UvrD to bind to 
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both strands. The interaction of ExoI or RecJ with UvrD probably determines loading 
ExoI or RecJ to SSB/ssDNA. If UvrD unwinding occurs on the 3' side of the mismatch 
(Figure 9A), this excision step is carried out by exonuclease I (which degrades a single 
strand only in the 3' to 5' direction).  If the unwinding occurs on the 5' side of the 
mismatch, exonuclease VII or RecJ is used to degrade the single stranded DNA in the 5’ 
to 3’ direction. 
  Figure 9 showed a simple model that may account for SSB help recruit ExoI and 
UvrD to SSB/ssDNA substrates, and also, make a direct interaction with UvrD. The 
complexes UvrD/ExoI/SSB loads at the nick and unwinds and excises the ss DNA from 
the nick towards the mismatch very efficiently. If the cleavage occurs on the 3' side of the 
mismatch (Figure 9A), this step is carried out by exonuclease I (which degrades a single 
strand only in the 3' to 5' direction).  If the cleavage occurs on the 5' side of the mismatch, 
exonuclease VII or RecJ is used to degrade the single stranded DNA in the 5’ to 3’ 
direction (Figure 9B).  The gap is filled by DNA polymerase III and DNA ligase.The 
mismatch repair system displays bidirectional capability (34, 35). Correction of a 
mismatched base can be directed by a hemimethylated GATC sequence on either the 5’ 
or 3’ side of the error. UvrD participates in the excision of the DNA biosynthetic error by 
unwinding from the nicked GATC site to a location past the error. Interestingly, UvrD 
preferentially unwinds from the nick toward the mismatch, regardless of whether the 
nicked GATC sequence is on the 5’ or 3’ side (35). This occurs despite the fact that 
helicase II alone catalyzes an unwinding reaction in both directions from a nicked DNA 
molecule in vitro (36). Because UvrD unwinds exclusively in a 3’ to 5’ direction with 
respect to the bound DNA strand (37, 38), bidirectional unwinding from a nick 
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necessitates the ability of UvrD to bind to both strands. It was shown that MutS 
translocates bidirectionally from a mismatch site in an ATP hydrolysisdependent fashion, 
creating a looped DNA structure that usually contains the mismatch (39). MutL 
stimulates the rate of this process and both proteins are found as a complex at the base of 
the loop structure. The arrival of the MutS–MutL complex at a GATC site activates the 
MutH-associated endonuclease and allows initiation of unwinding by UvrD from the 
resulting nick.  
The identification of an interaction between ExoI and UvrD may have important 
consequences for understanding mismatch repair in eukaryotic systems. Defects in 
eukaryotic mismatch repair result in destabilization of short repetitive sequences and 
have been linked to various cancers, most notably hereditary colon cancer (40, 41, 42, 
43). The error recognition steps of eukaryotic mismatch repair are somewhat more 
complex than in prokaryotes, but nevertheless occur by a similar mechanism involving 
homologs of the bacterial MutS and MutL proteins (44, 45). In fact, a number of 
eukaryotic mismatch repair genes were identified based on their homology to bacterial 
(Table1).  Despite the striking similarities between the initiation steps of prokaryotic and 
eukaryotic mismatch repair, very little is known about the subsequent steps in the 
eukaryotic pathway. For instance, an in vivo strand discrimination signal has not been 
discovered, and the mechanisms and proteins involved in excision and repair synthesis 
remain enigmatic. Of particular significance is the fact that no helicase has yet been 
identified as a participant in a eukaryotic mismatch repair system. It is possible that 
eukaryotic mismatch repair does not require a helicase; one or more exonucleases may be 
solely responsible for the excision step.  Four nucleases in MMR exist in yeast systems, 
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exonuclease 1 (Exo1), Rad27, and the 3’ exonucleases intrinsic to Pol ε and Pol δ (46, 
47). Currently, Exo1 is most clearly implicated that it interacted with MutS and MutL 
proteins (48, 49, 50, 51, 52). The discovery of a physical interaction between UvrD and 
ExoI in E.coli may lead to advances in our understanding of mismatch repair in 
eukaryotic systems. 
In summary, we have discoved the direct physical interactions of ExoI and UvrD 
in DNA mismatch repair and also, defined a model for understanding the recruiting roles 
of SSB in bacterial genome maintenance. We also discuss the possible surface on ExoI 
that possibly interact with UvrD. Knowledge of the ExoI/SSB/UvrD should help direct 
studies into how ExoI interacts with its binding partners and whether (and how) 
association with UvrD is regulated in cells. 
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Table I: MMR components and their functions 
 
 
E. coli                                                      Human                                                                 Function 
 
(MutS)2                                                                       hMutSα (MSH2-MSH6)a                                      DNA mismatch/damage recognition 
                                                         hMutSβ (MSH2-MSH3) 
 
(MutL)2                                                                       hMutLα (MLH1-PMS2)a                                      Molecular matchmaker; endonuclease,                 
termination of mismatch-provoked excision 
                                                         hMutLβ (MLH1-PMS1) 
                                                         hMutLγ (MLH1-MLH3) 
 
MutH                                               ?b                                                                                                  Strand discrimination 
 
UvrD                                                ?b                                                                                                  DNA helicase 
 
ExoI, ExoVII, ExoX, RecJ             ExoI                                                         DNA excision; mismatch excision 
 
Pol III holoenzyme                        Pol δ                                                   DNA re-synthesis 
 
                                                       PCNA                                                      Initiation of MMR, DNA re-synthesis 
 
SSB                                                RPA                                                         ssDNA binding/protection; stimulating  
mismatch excision; termination of DNA 
excision; promoting DNA resynthesis 
 
 
                                                      HMGB1                                                    Mismatch-provoked excision 
 
                                                      RFC                                                          PCNA loading; 3' nick-directed repair; 
activation of MutLα endonuclease 
 
DNA Ligase                                  DNA ligase I                                            Nick ligation 
 
 
a: Major components in cells. 
 
b: Not yet identified. 
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Figure legends 
 
FIGURE 1:   Mismatch repair.  The repairing process begins with the protein MutS 
which binds to mismatched base pairs.  Then, MutL is recruited to the complex 
and activates MutH which binds to GATC sequences.  Activation of MutH cleaves the 
unmethylated strand at the GATC site.  Subsequently, the segment from the cleavage 
site to the mismatch is removed by exonuclease (with assistance from helicase II and 
SSB proteins).  If the cleavage occurs on the 3' side of the mismatch, this step is carried 
out by exonuclease I (which degrades a single strand only in the 3' to 5' direction).  If 
the cleavage occurs on the 5' side of the mismatch, exonuclease VII or RecJ is used to 
degrade the single stranded DNA.  The gap is filled by DNA polymerase III and DNA 
ligase. The distance between the GATC site and the mismatch could be as long as 1,000 
base pairs.  Therefore, mismatch repair is very expensive and inefficient. Mismatch 
repair in eukaryotes may be similar to that in E. coli.  Homologs of MutS and MutL 
have been identified in yeast, mammals, and other eukaryotes.  MSH1 to MSH5 are 
homologous to MutS; MLH1, PMS1 and PMS2 are homologous to MutL.  Mutations of 
MSH2, PMS1 and PMS2 are related to colon cancer. In eukaryotes, the mechanism to 
distinguish the template strand from the new strand is still unclear.  
 
FIGURE 2: New expression vectors for use in two-hybrid analysis. (a) Structure of the 
pGAD-C(x) vectors.  Stippled regions indicate the ADHl promoter (P) and transcription 
termination (T) elements. GAL4 AD (activation domain) encodes amino acids 768-881. 
(b) Sequences of the polylinker regions. Restriction sites are underlined; stop codons are 
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boxed. *, single base pair insertions introduced during construction. EcoR I is present in 
one reading frame, Sma I in two, and all other sites in all three reading frames.  
 
FIGURE 3: Analysis of a partial digestion of genomic DNA using Southern blotting. 
The panel on the left shows a set of HinPlI partial digestion reactions separated by 
electrophoresis and stained with ethidium bromide. Enzyme concentrations are shown 
above each lane in units per microgram of DNA. Size markers are labeled on the left. The 
right panel shows a Southern blot of the same gel probed with a 315-bp fragment of the 
AnE2 gene. The fragment size that results from complete digestion is indicated by an 
arrow. 
 
FIGURE 4: The procedures of E. coli K12 genomic library construction 
 
FIGURE 5: Interaction of Exonuclease I and UvrD. Yeast strain HF7c was 
simultaneously transformed with plasmids pGBT9 (ExoI) and pGAD424-C1 (library), 
and cells were grown on synthetic medium lacking leucine and tryptophan (panel A) or 
lacking leucine, tryptophan and histidine (panel B). The ability of cells to grow on 
medium lacking histidine is dependent on the expression of the his3 gene under the 
control of a GAL1-responsive promoter. 
 
FIGURE 6:  ExoI and UvrD interact in the yeast two-hybrid system. Yeast HF7c cells 
containing various constructs of pGBT9 and pGAD424 were grown at 30°C on complete 
synthetic media lacking tryptophan, leucine and histidine, and supplemented with 1 mM 
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3-AT. Each quadrant on both plates contains cells streaked from a single transformant 
that was colony-purified. Labels for both panels represent the fusion proteins present in 
HF7c in the order: DNA binding domain/transcriptional activation domain. Minus (-) 
represents the absence of ExoI or UvrD from the fusion construct.  
 
FIGURE 7:  ExoI was specifically retained on an UvrD affinity column. 1 mg ExoI (A) 
or BSA (B) were loaded onto a 5 ml Ni-NTA beads containing 1 mg purified Histag 
UvrD as described in Materials and methods. In both (A) and (B): lanes 1, 2 and 3: flow-
through (FT) and washes; lanes 4 and 5, 250 mM imidazole elution. Gels were stained 
with Coomassie Brilliant Blue.  
 
FIGURE 8:  The structure of ExoI. The N-terminal domain (colored yellow) corresponds 
to the ‘exonuclease’ or ‘proofreading’ domain of the DNA polymerases and includes the 
catalytically essential residues. The second domain (colored green) has a structure akin to 
an elaborated SH3 domain. The residues toward the C-terminus (colored blue) form a 
helical region that extends the exonuclease domain. 
 
FIGURE 9: Showed a simple model that may account for SSB help recruit ExoI and 
UvrD to SSB/ssDNA substrates. If the cleavage occurs on the 3' side of the mismatch 
(Figure 9A), this step is carried out by complex ExoI/SSB/UvrD (which degrades a single 
strand only in the 3' to 5' direction).  If the cleavage occurs on the 5' side of the mismatch, 
exonuclease VII or RecJ/SSB/UvrD is used to degrade the single stranded DNA in the 5’ 
to 3’ direction (Figure 9B).  
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Figure 4 
 
Prepare E. coli K12 genomic DNA 
 
 
Partial digestion of genomic DNA  with “GC” enzyme AciI, HinP1I, MaeII, MspI and 
TaqI. Optimize the concentration of each enzyme by sothern blot 
 
 
Size fractionated the selected digests by gel electrophoresis 
 
 
Vectors pGAD-C1, C2, C3 were digested with ClaI, treating the cleaved ends with  
CIP 
 
Linear vectors were purified by electrophoresis 
 
 
15 independent ligations (Each of the three different frame vectors to each of the five 
different partial digestions) 
 
 
Each ligation mix was transformed to E. coli JS4 
 
 
Each reaction was inoculated to LB media, cultures were harvested in mid-log phase 
 
 
Mix the five cultures that represent each reading frame, produce three large cultures 
 
 
DNA was prepared from each of the three libraries 
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Figure 7 
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Abstract 
Werner Syndrome is a rare autosomal recessive disease characterized by a 
premature aging phenotype, genomic instability and a dramatically increased incidence of 
cancer and heart disease.  Mutations in a single gene encoding a 1,432 amino-acid 
helicase/exonuclease (hWRN) have been shown to be responsible for the development of 
this disease.  We have cloned, over-expressed and purified a minimal, 171-amino acid 
fragment of hWRN that functions as an exonuclease.   This fragment, encompassing 
residues 70-240 of hWRN (hWRN-N70-240), exhibits the same level of 3’-5’ exonuclease 
activity as the previously described exonuclease fragment encompassing residues 1-333 
of the full-length protein.  The fragment also contains a 5’-protruding DNA strand 
endonuclease activity at a single-strand/double-strand DNA junction and within single-
stranded DNA, as well as a 3’-5’ exonuclease activity on single-stranded DNA. We find 
hWRN-N70-240 is in a trimer-hexamer equilibrium in the absence of DNA when examined 
by gel filtration chromatography and atomic force microscopy (AFM). Upon the addition 
of DNA substrate, hWRN-N70-240 forms a hexamer and interacts with the recessed 3’-end 
of the DNA. Moreover, we find that the interaction of hWRN-N70-240 with the replication 
protein PCNA also causes this minimal, 171-amino acid exonuclease region to form a 
hexamer.  Thus, the active form of this minimal exonuclease fragment of human WRN 
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appears to be a hexamer.  The implications the results presented here have on our 
understanding of hWRN’s roles in DNA replication and repair are discussed. 
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Introduction 
Werner Syndrome (WS) is an autosomal recessive disease characterized by the 
early onset of an aged appearance along with the common disorders associated with 
advancing age (1, 2). These disorders include atherosclerosis, bilateral cataracts, diabetes 
mellitus, and osteoporosis, as well as an unusually high incidence of tumors of non-
epithelial cell origin. WS cells are characterized by chromosomal translocations, 
defective maintenance of telomeres, elevated rates of homologous recombination, large 
DNA deletions, and a prolonged S-phase of DNA synthesis (3, 4, 5, 6, 7, 8, 9, 10). WRN, 
the gene defective in WS, consists of 35 exons that encode a 1,432 amino acid protein 
(hWRN).  This protein functions both as a 3’ to 5’ DNA helicase and as a 3’-5’ 
exonuclease (6, 11, 12, 13).  In addition, one group has reported that hWRN is also a 5’ 
to 3’ exonuclease (14). The sequence of the helicase domain is homologous to members 
of the RecQ family of DNA helicases (15). This family includes Escherichia coli RecQ, 
Saccharomyces cerevisiae Sgs-1p, Schizosaccharomyces pombe Rqh-1p, human RecQL, 
and the protein associated with Bloom Syndrome, BLM (16, 17, 18, 19, 20). Of the RecQ 
helicases identified so far, only the WRN protein functions both as a helicase and as an 
exonuclease. How these two functions are coupled during DNA metabolic events in vivo 
remains unclear.  
The conserved exonuclease motif of WRN is located in the N-terminus, while the 
RecQ helicase motif is more centrally located with respect to the N- and C-termini. It has 
been shown that hWRN can efficiently degrade 3’ recessed DNA strands of double-
stranded or DNA-RNA heteroduplexes (12, 13). hWRN has little activity on blunt-ended 
DNA, on DNA with a 3’ protruding strand, or on single-stranded DNA (5). In the 
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presence of the Ku 70/80 heterodimer, however, the exonuclease activity of hWRN is 
altered.  For example, hWRN is stimulated to degrade blunt-ended and single-stranded 
DNA substrates in a 3’-5’ direction in the presence of Ku (21, 22, 49, 50).   The 
interaction of hWRN with the Ku heterodimer is mediated by residues 1-50 of hWRN 
(50).  
Information obtained from protein sequence database searches revealed that the 
exonuclease domain of hWRN is contained within the first 333 amino acids at the N-
terminus (5).  This region exhibits significant similarity to the 3’ to 5’ proofreading 
domain of E. coli polymerase I, RNAseD and the nuclease domain of the human 
polymyositis/scleroderma nuclear autoantigen (23). Within this N-terminal exonuclease 
region, five amino acids (Asp82, Glu84, Asp143, Tyr212 and Asp216) are proposed to be 
critical for exonuclease activity (5).  
The biological function of the WRN helicase/exonuclease is unclear. It is possible 
that WRN participates in one or more aspects of DNA replication because abnormalities 
in both S-phase initiation and transition have been reported in cells harboring WRN 
mutations (5, 24). Its efficient removal of terminally mismatched nucleotides raises the 
possibility that WRN may provide a 3' to’5' proofreading activity for DNA polymerases 
that lack such an activity (25). The findings that WRN interacts with numerous proteins 
involved in DNA replication, recombination and repair, including PCNA (5, 26), Ku (21, 
22, 49, 50), p53 (27), RPA (28, 29), DNA Pol δ and topoisomerase I (30, 31, 32, 33), 
support the involvement of WRN in these processes, as well. 
To gain a better understanding of the functions of the WRN exonuclease, we have 
performed a detailed analysis of the physical and biochemical properties of a minimal 
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fragment comprising amino acids 70-240 at the N-terminus of hWRN (hWRN-N70-240). 
We show, through a variety of techniques, that: 1) hWRN-N70-240 is capable of 
hydrolyzing double-stranded DNA with a 3’ recessed end in a 3’ to 5’ direction; 2) 
hWRN-N70-240 exhibits a 5’-protruding strand endonuclease activity and a 3’-5’ 
exonuclease activity on single-stranded DNA; 3) hWRN-N70-240 is in a trimer-hexamer 
equilibrium in the absence of substrate; 4) hWRN-N70-240 forms a hexamer on a DNA 
substrate containing a recessed 3’-end; and 5) the interaction of hWRN-N70-240 with 
PCNA causes hWRN-N70-240 to form a hexamer. These results indicate that this minimal 
exonuclease region of hWRN is active as a hexamer and is capable of functioning both as 
an exonuclease and an endonuclease.  The implications these results have on our 
understanding of the nuclease functions of full-length WRN are discussed. 
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Materials and Methods  
Materials  
The expression vector pET15b and BL21(DE3) cells were obtained from 
Stratagene. The Ni-NTA resin was from Qiagen. Superdex 200 resin was purchased from 
Bio-Rad, and DEAE sepharose from Pharmacia. [γ-32P]-ATP was obtained from NEN 
Life Science Products. Bacteriophage T4 polynucleotide kinase was supplied by New 
England Biolabs. Deoxyribonucleoside triphosphates were purchased from Promega, and 
ribonucleoside triphosphates (NTPs) were supplied by GibcoBRL. Oligonucleotides 
(Table I), purchased in-house (UNC-Chapel Hill), were purified by HPLC. The full-
length human WRN cDNA was a gift of Drs. Matthew Gray and George Martin of the 
University of Washington, Seattle.  AFM tips were purchased from Molecular Imaging, 
Inc., Phoenix, AZ. 
 
Purification of hWRN-N70-240  
hWRN-N70-240 and hWRN-N1-333  codons were amplified by polymerase chain 
reaction (PCR) and cloned into pET15b expression vector to generate pET15b-hWRN-
N70-240 and pET15b-hWRN-N1-333. The point mutation E84A (Glu → Ala at amino acid 
84) was introduced by site-directed PCR mutagenesis to generate pET15-hWRN-N70-240 
E84A. The cloned hWRN sequence, exonuclease mutation and cloning in frame to the 
hexa-His-tag in the expression vectors were verified by DNA sequencing. Recombinant 
proteins were produced according to the supplier’s protocol. Cells were lysed in 20 mM 
Tris-HCl, pH 7.8, 300 mM NaCl, 5% glycerol, 1 mM phenylmethylsulfonyl fluoride 
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(PMSF), 1 mM β-ME and disrupted with a sonicator. The lysate was clarified by 
centrifugation and incubated with Ni-NTA resin at 4 °C for 1 h. The resin was then 
washed with 20 mM Tris-HCl, pH 7.8, 300 mM NaCl, 5% glycerol and protein was 
eluted with 20 mM Tris-HCl, pH 7.8, 300 mM NaCl, 5% glycerol, 250 mM imidazole. 20 
mM DTT was added into the eluted protein. The protein sample was heated at 37 °C for 
15 minutes with 100 mM DTT addition and loaded onto a Superdex S-200 column (80 
cm), which was previously equilibrated in buffer A (20 mM Tris-HCl, pH 7.8, 30 mM 
NaCl, 5% glycerol). Pooled fractions of hWRN-N70-240 from Superdex S-200 were finally 
subjected to anion exchange chromatography (Q-sepharose fast flow). The column was 
pre-equilibrated in buffer A before loading protein. After washing the column with 1 
column volume of equilibration buffer, proteins were eluted by successive washes with 
three to four column volumes with each of buffer A containing 50, 100, 150, 200 mM 
NaCl. SDS-PAGE resolution followed by Coomassie Blue staining of proteins indicated 
that the major protein of the ~22 kDa hWRN-N70-240 protein was present in 150 mM 
NaCl eluate. Pooled hWRN-N70-240 fractions with a typical total protein content of 5 – 7 
mg were concentrated to 10 mg / ml in the same buffer. The concentrated hWRN-N70-240 
proteins were resolved by SDS-PAGE and assayed for DNA exonuclease activity. The 
activity remained stable for at least 1 month at – 80 °C. Protein concentrations were 
determined by Bradford assay.  hWRN-N1-333 and hWRN-N70-240E84A were purified in a 
fashion identical to that performed for hWRN-N70-240.   
 
DNA Labeling and Annealing 
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 Single-stranded DNA oligomers were labeled with 32P at their 5’ ends as 
described in Molecular Cloning (34). To form the partial DNA duplex for exonuclease 
activity assay, the labeled oligomer was mixed with the complementary unlabeled DNA 
oligomer (1:1) in 50 mM Tris – HCl, pH 7.8, 5 mM MgCl2. The DNA mixture was 
heated to 100 °C for ten minutes and then allowed to anneal slowly by cooling to room 
temperature overnight. The resulting partial duplex contained a 3’ recessed terminus was 
ethanol-precipitated two times and resuspended in 100 µl dd H2O. 
Assays for WRN Nuclease Activities 
 
32P-labeled DNA substrate (0.1 pmol) was incubated with 25 fmol of recombinant 
hWRN-N70-240 at 37 °C in a 10 µl reaction mixture containing 40 mM Tris-HCl, pH 7.4, 4 
mM MgCl2, 5 mM DTT, 100 µg/ml BSA and 1 mM ATP. The protein was incubated 
with DNA for increasing lengths of time and DNA hydrolysis was terminated by addition 
of quench buffer (0.5 mM EDTA and 80% formamide). At the time points indicated (e.g., 
in Figure 2B: 0, 1, 2, 5, 10, 15, 20, 30 and 40 min), 4 µl of quench buffer were added to 8 
µl of the reaction mixture. An aliquot of 6 µl of denaturing loading buffer (76% 
formamide, 20 mM EDTA, 2% SDS, 3% bromophenol blue, 3% xylene cyanol) was 
added to 6 µl of the stopped reaction mixture. The mixture was heated at 100 °C for 1 
min prior to electrophoresis on a 8 M urea/20% polyacrylamide gel in 1 X TBE (90 mM 
Tris base, 90 mM boric acid, 1 mM EDTA). Gels were vacuum-dried and reaction 
products were visualized by autoradiography and quantified by PhosphoImager 
(Molecular Dynamics, Amersham Pharmacia Biotech, Piscataway, NJ).  Assays 
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involving hWRN-N1-333 and hWRN-N70-240E84A were performed identically to those 
described for hWRN-N70-240.   
 
Determination of Oligomerization State of hWRN-N70-240  
 Ni-NTA affinity purified hWRN-N70-24 (100 µg/100 µl) was treated with 50 mM 
EDTA and 100 mM DTT for 15 min at 37 °C and then subjected to gel filtration at 4 °C. 
The column was Superdex S-200 (80 cm), the flow rate was 0.5 ml/min and fraction size 
was 2 ml. Protein was eluted with 20 mM Tris-HCl, pH 7.8, 30 mM NaCl and 0.1 mM 
PMSF. The column was calibrated using ferritin (440 kDa), aldolase (158 kDa), 
ovalbumin (43 kDa) and ribonuclease A (13.7 kDa). The elution profiles of WRN were 
examined by SDS-PAGE. 
 
Atomic Force Microscopy 
• Protein and DNA Preparation 
 The imaged DNA was prepared using standard PCR techniques. The DNA used 
was a 1000 bp segment that was PCR amplified from M13 phage DNA and digested by 
BamHI and Ban II restriction enzymes (named L substrate; Table I). Digested fragments 
were isolated from 0.8% agarose gels utilizing Qiagen gel extraction kit and then, 100-bp 
fragment was ligated into the Ban II digested end. Yeast proliferating cell nuclear antigen 
(yPCNA) was a gift from Dr. Tom Kunkel of NIEHS. hWRN-N70-240 was prepared as 
described above. 
• Imaging by Atomic Force Microscopy (AFM)  
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  Imaging was performed with Nanoscope IIIa instrument (Digital instrument, 
Santa Barbara, CA) using TappingR mode in air. Nanosensor PointprobeR non-
contact/tappingR mode sensors with spring constants of 48 N/m and resonance 
frequencies of 190 KHz were used for all images. The protein and DNA molecules were 
deposited onto freshly cleaved mica (Spruce Pine Mica Co., Spruce Pine, NC), washed 
with deionized distilled water, and dried with a stream of N2 (gas). To obtain the proper 
surface coverage, the deposition time was varied from 5 to 60 seconds depending on the 
protein and DNA concentrations. All images were collected at a scan rate of 3.0 Hz and a 
scan size of 1 µm.  Volume analysis using AFM data was performed using image 
planefitting, image analysis and volume calculation, as described (35).   
• hWRN-N70-24 – yPCNA  Binding Reactions 
Binding reactions included 100 nM hWRN-N70-240, 400 nM yeast proliferating cell 
nuclear antigen (yPCNA), 20 mM Tris-HCl, pH 7.8, 30 mM NaCl, 1 mM ATP, 5 mM 
MgCl2 and 5% glycerol in 20 µl. After incubation for 15 min at room temperature, the 
reaction mixtures were diluted to 200 µl with binding buffer (20 mM Tris-HCl, pH 7.8, 
30 mM NaCl, 5 mM MgCl2 and 5% glycerol) and 20 µl were immediately deposited onto 
freshly cleaved mica. 
• hWRN-N70-24 – DNA Binding Reactions  
Two substrates were used in the binding reactions: one is a short piece of DNA 
named substrate S with a top strand of 20 nucleotides and a bottom strand of 46 
nucleotides (see Table I); the other is substrate L, which contains a 100-base 5’-overhang 
as described above. Binding reactions included 3-4 nM DNA fragment, 400-500 nM 
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hWRN-N70-240, 20 mM Tris-HCl, pH 7.8, 30 mM NaCl, 5 mM MgCl2 and 5% glycerol in 
20 µl. After incubation for 15-20 min at room temperature, the reaction mixtures were 
diluted to 200 µl in binding buffer (20 mM Tris-HCl, pH 7.8, 30 mM NaCl, 5 mM MgCl2 
and 5% glycerol) and 20 µl were immediately deposited onto freshly cleaved mica. 
• Volume Calculations  
The measured AFM volumes, calculated using the equation Vi = Ai *(Mi - S), of each 
of the proteins were distributed in a Gaussian fashion (35). The volume and its 
uncertainty for a given protein were taken to be the average and standard deviation of the 
distribution. The area Ai, total average height Mi, and surface heights are measured using 
ImageSXM software. Prior to volume analysis, the deposition time that produced optimal 
surface coverage was determined. The data were filtered to remove false positives of 
oligomers using major: major axis ratio cut-off values ranging from 2.0 to 2.5. Histogram 
plots of the volume of the proteins were generated for each cut-off value. 
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Results  
Cloning , Expression and Purification of hWRN-N70-240 and hWRN-N1-333 
The hWRN exonuclease activity resides within the first 333 amino acids at the N-
terminus of the protein (5). In aligning the hWRN and mouse WRN sequences (mWRN), 
we found that the region between amino acids 70 and 240 (Fig. 1) exhibits 83% amino 
acid identity and includes all five amino acids (Asp82, Glu84, Asp143, Tyr212 and 
Asp216) predicted to be critical for hWRN exonuclease activity (5).  To determine if this 
region of hWRN was sufficient to function as an exonuclease, we cloned, expressed and 
characterized a minimal fragment of the WRN exonuclease comprised of residues 70-240 
and analyzed it relative to the N-terminal 333-amino acid exonuclease fragment of WRN 
described previously (5). 
Regions of the hWRN cDNA encoding amino acids 70 to 240 and 1 to 333 were 
amplified by the polymerase chain reaction (PCR) and cloned into pET15b to generate 
pET15b-hN1-333 and pET15b-hN70-240.  In addition, the point mutation E84A (Glu to Ala 
at amino acid 84), previously shown to inactivate the exonuclease activity of full-length 
hWRN (5), was introduced by site-directed PCR mutagenesis to generate pET15b-hN70-
240E84A. The cloned hWRN-N70-240, hWRN-N1-333, and hWRN-N70-240E84A regions were 
confirmed by DNA sequencing and inserted in-frame to allow the production of hexa-
His-tagged proteins.   
The recombinant hWRN-N1-333 and hWRN-N70-240 proteins were expressed in 
BL21 (DE3) pLys cells, and purified by Ni-affinity batch preparation, gel filtration 
chromatography using a Superdex S-200 column and finally, Q-sepharose fast flow. At 
the gel filtration step, the recombinant hWRN proteins eluted as a trimer as judged by 
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apparent molecular weight, and were found to be ~80% pure by SDS-PAGE. After anion 
exchange chromatography, proteins were estimated to be >95% pure based on Coomassie 
blue stained SDS-PAGE.  Purified hWRN-N70-240 had an apparent monomeric molecular 
weight of 21 kDa, as expected from the calculated molecular weight with the additional 
N-terminal 20 amino acids encoded by the hexa-His-tag and vector. Purified hWRN-N1-
333 and hWRN-N70-240 E84A had apparent molecular weights of 40 kDa and 21kDa, 
respectively.  
 
 hWRN-N70-240  is a 3’-5’ Exonuclease 
We assayed the exonuclease activity of hWRN-N70-240 using a 5’-labeled, 3’-
recessed double-stranded DNA substrate composed of a 24-nucleotide top strand and a 
60-nucleotide bottom strand which we will refer to as substrate R (see Table I and Figure 
2A). As shown in Figure 2, hWRN-N70-240 and hWRN-N1-333 both catalyze the 
exonucleolytic hydrolysis of the 3’-recessed end of this double-stranded DNA duplex in a 
3’-to-5’ direction. Cleavage of substrate radiolabeled at the 5’-terminus yields time-
dependent accumulation of shorter products.  In our hands, both hWRN-N70-240 and 
hWRN-N1-333 function as relatively non-processive 3’-5’ exonucleases.  In particular, 
hWRN-N70-240 appears to degrade DNA substrate R efficiently through the G6 region (see 
Table I) but not beyond that.  No detectable hWRN-N70-240 nuclease activity was 
observed using the hWRN-N70-240E84A construct of human WRN.  Similarly, no hWRN-
N70-240 nuclease activity was observed with single-stranded DNA alone (i.e. not an 
overhang from a DNA duplex), blunt-ended DNA, or a DNA duplex containing a 5’-
rececced end (data not shown). These results suggest that hWRN-N70-240 exonuclease is 
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distinguished from the large majority of the known nucleases by its preference for 3’ 
recessed DNA in a partial duplex.  
 
hWRN-N70-240  Appears Trimeric By Gel Filtration Chromatography 
Once we established that the minimal 70-240 region of hWRN functioned as an 
exonuclease, we next sought to characterize the oligomeric state of this fragment in vitro.  
The 1-333 fragment of hWRN was previously reported to be a trimer based on gel 
filtration chromatography (5). To determine the oligomeric structure of hWRN-N70-240, 
we also employed gel filtration chromatography. Purified hWRN-N70-240 was re-applied 
to the Superdex S-200 column used for protein purification (Figure 3A). A set of standard 
proteins was also assayed in separate runs on the same gel filtration column (see 
Materials and Methods), and their elution volumes were used to construct a standard 
curve.  The hWRN-N70-240 was found to elute in a peak corresponding to a molecular 
mass of 65 kDa (Figure 3A and Figure 3B). As the molecular mass of the recombinant 
hWRN-N70-240 is ~21 kDa, the oligomerization state of this population of the protein 
appears to be trimeric. 
 
hWRN-N70-240 is in a Trimer-Hexamer Equilibrium by AFM 
Atomic force microscopy (AFM) can be used to image soft samples with 
nanometer resolution both in air and in solution (35). We used it to quantify 
intermolecular protein and protein-DNA interactions. Because AFM produces 
topographical images, it is possible to relate the molecular weight of a protein to its 
volume. Previous studies have shown a linear relationship between the measured AFM 
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volume and the molecular weight of the proteins by the equation v = (1.3 * MW) – 25, 
where v is the volume measured by AFM and MW is the molecular mass (35). 
Furthermore, the expected AFM volume of oligomeric protein complexes can be 
predicated using this equation. Table II shows the possible hWRN-N70-240 complexes 
considered in this study.  
To determine the oligomerization state of this minimal exonuclease fragment of 
human WRN, hWRN-N70-240, it was deposited at 20 nM, images were collected and 
volume analysis was performed for each set of images. Figure 4A shows an ideal hWRN-
N70-240 surface coverage for volume analysis. 1135 protein data points were analyzed and 
a histogram of molecular volumes for hWRN-N70-240 is shown in Figure 4B. The 
distribution has a major peak at ~60 nm3 with a shoulder at higher volumes.  The major 
peak was fit to a Gaussian function to determine the volume. The observed AFM volume 
is (60 ± 5) nm3, which corresponds to a molecular weight of 66 kDa.  This mass is 
consistent with a trimer of hWRN-N70-240 (see Table II). The small peak at ~140 nm3 is 
consistent with the molecular weight of hWRN-N70-240 hexamer (125 kDa). 
Approximately 10% of the hWRN-N70-240 is in the higher association state (hexamer). 
This result is consistent to the previous report that 90% wild type hWRN existed as 
trimer in the absence of DNA (5).  
  
hWRN-N70-240 Interacts with Trimeric PCNA as a Trimer and a Hexamer 
Human PCNA, which is a major component of the DNA replication fork, has been 
reported to interact with hWRN (5, 26). To determine if PCNA interacts with the minimal 
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WRN fragment hWRN-N70-240, we imaged Saccharomyces cerevisiae PCNA (yPCNA) 
alone and in complex with hWRN-N70-240 by AFM.  Human PCNA shares 35% sequence 
identity with yPCNA, and the three-dimensional structures of these two trimeric proteins 
are highly similar (36). We used AFM to determine the oligomerization state of yPCNA 
and in complex with hWRN-N70-240. As expected, yPCNA exists as a trimer with the 
molecular weight of ~92 kDa (Figure 5A). Inspection of Figure 5A reveals a single peak 
at ~90 nm3.  With hWRN-N70-240 and yPCNA together, two distinct peaks are observed at 
150 nm3 and 235 nm3 (Figure 5B).   These peaks correspond to the molecular weights of 
135 kDa and 200 kDa, respectively.  Based on Table II, the first peak (135 kDa) can be 
explained by two species: one is a complex of a trimer yPCNA and a trimer hWRN-N70-
240 (150 kDa); the other one is a hexamer of hWRN-N70-240 (126 kDa). However, as 
shown above by two methods, hWRN-N70-240 is a trimer in the absence of DNA (Figures 
3-4). In addition, the disappearance of the peak corresponding to the trimer of PCNA 
from Figure 5B provides strong evidence that the two peaks present in this figure contain 
PCNA and hWRN-N70-240.  Thus, we conclude that the first peak represents trimer 
PCNA: trimer hWRN-N70-240 complexes. The second peak (200 kDa) can be explained by 
trimer yPCNA: hexamer hWRN-N70-240 complexes (213 kDa), or by hexamer yPCNA: 
trimer hWRN-N70-240 complexes (237 kDa).  Because there is no evidence for PCNA 
hexamer formation, we conclude that the second peak is generated by complexes of 
yPCNA trimers and hWRN-N70-240 hexamers.  Thus, yPCNA and hWRN-N70-240 form 
both trimer-trimer and trimer-hexamer complexes.  Further, the interaction of PCNA with 
hWRN-N70-240 appears to drive the formation of hWRN-N70-240 hexamers.   
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hWRN-N70-240 Hexamerizes on DNA   
 In several previous studies, AFM was used for qualitative analyses of several 
protein-DNA complexes, including that of Cro protein, RNA polymerase, and Heat shock 
transcription factor-2 with double-stranded DNA, and the interaction of single-stranded 
DNA-binding proteins and single-stranded DNA (37, 38, 39, 40). These successful 
applications of AFM have made it possible to extend the use AFM to the quantitative 
analysis of DNA-protein interactions. To test whether hWRN-N70-240 exists as trimer or 
as a higher-order oligomer in the presence of DNA, AFM images were obtained in the 
presence of substrate S, a 3’-recessed double-stranded DNA molecule composed of a 20 
nucleotide top strand and a 46-nucleotide bottom strand (Table I, Figure 6A). This DNA 
substrate is too small, with a maximal expected length of 7 nm, to be visualized by AFM.  
A statistical analysis reveals that the volume distribution of hWRN-N70-240 molecules on 
DNA substrate S is best explained by the existence of two populations of hWRN-N70-240 
molecules with two different sizes (Figure 6B): 45% as 60 nm3 and 49% as 135 nm3. 
Based on the volumes in Table II, the smaller and larger populations are considered to be 
trimers and hexamers, respectively. In the absence of DNA, this hexamer peak is not 
present (Figure 4B).  Because the size of the small DNA substrate S can be neglected in 
AFM images, we thus conclude that hWRN-N70-240 efficiently hexamerizes in the 
presence of DNA.   
We next sought to visualize directly complexes of hWRN-N70-240 and DNA.  A 
longer DNA substrate L (1 kb) was used which contained a recessed 3’- end formed by a 
100-base 5’-overhang (Table I).  This DNA substrate was visualized alone by AFM and 
revealed molecules of between 305 and 315 nm in length, as expected (Figure 6C).  Upon 
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the addition of hWRN-N70-240, it is possible to visualize hWRN-N70-240 complexes 
associating with one end of this DNA substrate (Figure 6D).  Based on the activity 
studies presented above, we conclude that hWRN-N70-240 is associating with the recessed 
3’-end of the DNA substrate.   
These AFM studies also revealed an unexpected observation: upon incubation of 
hWRN-N70-240 with the 1 kb DNA substrate L for 15 minutes with 1 mM ATP, we 
visualized the accumulation of smaller DNA fragments (e.g., Figures 6E-F).  These are 
not the product of efficient 3’-5’ exonuclease activity by hWRN-N70-240, as that would 
produce DNA molecules with single-strand DNA ends that would still appear long by 
AFM (35).  The fragments observed ranged in length from ~300 nm to as small as 37 nm 
(roughly 900 bp to 110 bp, respectively), with intermediate sizes such as 141 nm and 91 
nm (430 bp and 275 bp, respectively) also present.  We hypothesized these smaller DNA 
fragments were the product of a novel, protruding-strand endonuclease activity associated 
with hWRN-N70-240.   This activity would involve the cleavage of the intact DNA strand 
opposite from the recessed 3’-end.  A more detailed examination of this activity is 
described below.  
 
hWRN-N70-240  Exhibits a 5’-Protruding Strand DNA Endonuclease Activity 
Because AFM images of hWRN-N70-240 incubated with DNA substrate L reveal 
the accumulation of smaller DNA fragments (Figures 6E-F), we suspected that hWRN-
N70-240 contained a novel nuclease activity.  As stated above, we hypothesized that these 
smaller fragments were the product of the cleavage of the intact DNA strand opposite 
from the 3’-recessed DNA strand in substrate L.  To examine the effect of hWRN-N70-240 
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on a 5’-overhang in a DNA substrate, we employed the same substrate examined in the 
studies presented in Figure 2, but radiolabeled the 5’-end of the 60-mer, rather than the 
5’-end of the 24-mer (Table I; unlabeled 24-mer/5’-32P-labeled 60-mer). As shown in 
Figure 7, hWRN-N70-240 was found to exhibit endonuclease activity at three sites within 
this substrate.  First, a burst of cleavage appears to occur at two sites:  at the single-
strand/double-strand DNA junction, which generates the 36 base product, and within the 
single-stranded region of the 5’-protruding strand, which generates the 12 base product.  
Second, a cleavage occurs in the single-stranded, 5’-overhang region at the T12-GAAC 
junction; this generates the 24 base product.  The enzyme also appears to function as a  
3’-5’ exonuclease on the single-stranded DNA products. This effect is most obvious in 
the degradation of the 24 base product to generate a ladder of smaller products, although 
it can also be seen in the transient degradation of the 36 base and 12 base products as 
well.  It is possible that the 24 base product is generated not from an endonuclease 
cleavage, but from the 36 base product by efficient 3’-5’ exonuclease action through the 
T12 region which then slows when it reaches the non-poly-T sequence.  Products 
intermediate in length between 36 and 24 nucleotides are evident in the early time points 
in Figure 7.  In summary, hWRN-N70-240 contains an 5’-protruding strand endonuclease 
activity at a single-strand/double-strand DNA junction and within the single-stranded 
region of the 5’-protruding strand.  hWRN-N70-240 also appears to contain a 3’-5’ 
exonuclease activity on the single-stranded DNA products generated from its 
endonuclease action.  The functional implications of these additional activities are 
discussed below. 
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Discussion 
In our examination of a 171-amino acid exonuclease fragment of the WRN 
helicase/exonuclease (hWRN-N70-240), we have found that this small construct contains 
3’-5’ exonuclease activity (Figure 2), and forms a hexamer in the presence of DNA 
(Figure 6).  We have further shown that hWRN-N70-240 is able to cleave a 5’-protruding 
strand at the single-strand/double-strand DNA junction and within the single-stranded 
region of the DNA.  The biological importance of the hexamer formation and these 
additional nuclease activities of hWRN-N70-240 is discussed below. 
A 333-amino acid N-terminal fragment of the WRN protein containing the 
exonuclease region was thought be a trimer based on examinations by gel filtration 
chromatography (5).  We similarly found that our minimized, 171-amino acid region of 
the WRN exonuclease (hWRN-N70-240) appears to be a trimer by gel filtration (Figure 3).  
An analysis of hWRN-N70-240 by atomic force microscopy, however, revealed that 
hWRN-N70-240 is in a trimer-hexamer equilibrium in the absence of DNA with the trimer 
being the major species (Figure 4).   We further found using AFM that the 
oligomerization state of hWRN-N70-240 is dramatically shifted toward hexamers in the 
presence of a small DNA substrate S (Table I; Figure 6A-B).  In addition, we visualized 
directly hWRN-N70-240 hexamers bound to one end of a 1 kb piece of DNA (Figure 6D).  
These observations suggest that the active form of hWRN-N70-240, and by extension the 
exonuclease region of full-length WRN, is a hexamer rather than a trimer. 
WRN represents the first example of an exonuclease that is a hexamer.  The 226-
amino acid 5’-3’ exonuclease from lambda phage, which participates in phage 
recombination and double-strand break repair, is a trimer in the x-ray crystal structure 
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(41).  This toroidal structure was determined in the absence of DNA, but was proposed to 
wrap around a DNA substrate to facilitate highly processive exonucleolytic cleavage of 
DNA.  The WRN exonuclease region may exist as an analogous toroidal trimer in the 
absence of DNA, and these toroidal trimers may stack to form a WRN exonuclease 
hexamer in the presence of DNA.  Alternatively, the WRN exonuclease hexamer may 
form a toroid, with the trimeric form of the protein existing as a half-toroid structure. 
The oligomerization state of the full-length WRN protein is unknown.  Based on 
its similarity to the BLM protein, which is hexameric (42), WRN may form a hexamer.  
Indeed, one critical difference between WRM and BLM is the presence of the 
exonuclease region in WRN, which may impact the oligomerization state of WRN.  
However, the WRN exonuclease region alone appears to form a hexamer, an observation 
which supports the suggestion that full-length WRN is a hexamer.  Such a conclusion is 
further supported by the finding that the interaction of hWRN-N70-240 with PCNA appears 
to drive the formation of hWRN-N70-240 hexamers (Figure 5).   PCNA is composed of a 
trimer of pseudo-dimers, which together form a toroid ring (43).  The observation that 
interactions with PCNA drive the formation of hWRN-N70-240 hexamers suggests that the 
hWRN-N70-240 hexamer structure may be a single toroid composed of two half-toroidal 
trimers, and that the hWRN-N70-240 and PCNA toroids stack.  The formation of WRN 
exonuclease hexamers on PCNA may in turn stabilize the hexameric form of the full-
length WRN protein as well. 
In examining the interaction of hWRN-N70-240 with the 1kb DNA substrate L by 
AFM, smaller DNA fragments with no evidence of long single-stranded ends were noted 
(Figures 6E-F).  Double-stranded DNA products near 1 kb in size (e.g., 900 bp) were 
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observed, as well as products of between 430 and 110 bp in length.  Based on these 
observations, we sought to determine if the WRN exonuclease region is able to cleave the 
5’-protruding strand near a single-strand/double-strand DNA junction.  We found that 
hWRN-N70-240 is capable of cleaving such a 5’-protruding strand at the single-
strand/double-strand DNA junction, as well as within the single-stranded region of the 5’-
protruding strand (Figure 7).  In addition, it appeared that hWRN-N70-240 further degraded 
these single-stranded DNA products using its 3’-5’ exonuclease activity (Figure 7).  
Thus, the activities of hWRN-N70-240 can be expanded to include not only a 3’-5’ 
exonuclease acting on the recessed 3’-end of duplex DNA, but also a 5’-protruding strand 
endonuclease activity and a 3’-5’ exonuclease activity on single-stranded DNA. 
In previously published reports it was shown that full-length hWRN can cleave a 
1 nucleotide 5’-flap imbedded within a DNA duplex; these authors further showed that 
the interaction of hWRN with the flap endonuclease Fen1 stimulates Fen1’s ability to act 
on an identical substrate containing a 5’-flap (58).   In addition, it was recently shown 
that the interaction of the Ku 70/80 heterodimer with a construct of hWRN encompassing 
residues 1-388 stimulates this hWRN fragment to degrade single-stranded DNA with a 
3’-5’ polarity (50).  Thus, human WRN appears to harbor the ability to perform multiple 
nuclease actions depending on the DNA substrate and hWRN’s interaction with other 
proteins.  Ku is known to interact with the residues 1-50 of hWRN (50).  Perhaps this 
interaction changes the positioning of these first 50 amino acids of hWRN, expanding the 
capabilities of the nuclease region of hWRN to include both endonuclease and 
exonuclease actions on single-stranded DNA.  Perhaps we were able to detect this 
activity without the presence of the Ku heterodimer because hWRN-N70-240 lacks these 
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first 50 amino acids.  These first 50 amino acids of hWRN may serve as a regulatory 
region that controls the nuclease action of the enzyme. 
The protruding strand endonuclease function of hWRN suggests an interesting 
new similarity with the Mre11 nuclease.  Mre11 forms a complex with the Nbs1 and 
Rad50 proteins, and this complex plays important roles in DNA double-strand break 
repair and meiotic recombination in eukaryotes (44, 45, 46).  Mre11 is a 3’-5’ 
exonuclease in the absence of ATP; upon the addition of ATP, however, Mre11 is 
stimulated to cleave the 3’-protruding strand at a DNA single-strand/double-strand 
junction (47).  WRN is also a 3’-5’ exonuclease and cleaves a protruding strand near a 
DNA single-strand/double-strand junction; in contrast to Mre11, however, WRN cleaves 
a 5’-protruding strand rather than a 3’-protruding strand.  Parallel biological roles for 
WRN and the Mre11 complex have been suggested previously because genetic 
experiments indicate the Mre11 complex is required for efficient end joining in S. 
cerevisiae double-strand break repair (48).    In addition, WRN has been implicated in the 
mammalian end-joining pathway through its association with the Ku 70/80 heterodimer 
(21, 22, 49, 50). Ku70/80 initiates end-joining in eukaryotes by binding to double-strand 
DNA breaks (51).  Mre11 is thought to facilitate the joining of double-strand breaks by 
removing non-complementary overhangs or damaged bases at broken ends by its ability 
to combine exonuclease and endonuclease activities (47).  Perhaps WRN’s largely 
analogous activities allow it to substitute for Mre11 in this process in human cells.  
Alternatively, WRN’s opposite polarity in protruding strand cleavage (5’ vs. 3’ for 
Mre11) suggests that WRN may be called upon to cleave 5’-overhangs to generate 
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double-strand DNA breaks, which can then be processed by the Ku heterodimer and the 
Mre11 complex. 
WRN has also been proposed to function in DNA replication, and its physical 
interaction with PCNA supports this role (5).  The identification of a 5’-protruding strand 
endonuclease activity associated with the WRN exonuclease region suggests a specific 
role for WRN in DNA replication.  During lagging strand synthesis, regions of Okazaki 
fragments are displaced by a helicase and the 5’-protruding ends are cleaved by the flap 
endonuclease Fen1 (52).  DNA ligase I seals the nicks remaining at the final stages of 
lagging strand synthesis (53).  Both Fen1 and DNA ligase I are also known to interact 
physically with PCNA (54, 55, 56, 57); in addition, as stated above, Fen1 and WRN are 
known to interact via the helicase region of WRN, and this interaction stimulates Fen1’s 
5’-flap endonuclease activity (58).  WRN may be capable of combining a Fen1-like 
nuclease activity with a helicase function, thereby efficiently coupling these two activities 
during Okazaki fragment removal.  The WRN helicase region could break Watson-Crick 
base pairs, and the 5’-protruding endonuclease activity of the WRN exonuclease region 
could cleave the resulting flap.  Thus, WRN may be capable of acting in concert with or 
substituting for Fen1 and other proteins in lagging strand synthesis under particular 
conditions within the cell.   
In summary, our results indicate that the active form of the WRN exonuclease is a 
hexamer, and that the interaction of the WRN exonuclease region with PCNA aids in the 
formation of WRN exonuclease hexamers.  The formation of WRN exonuclease 
hexamers may be linked to, or the consequence of, the formation of full-length WRN 
protein hexamers.  We have further found that the WRN exonuclease region exhibits a 
 68 
5’-protruding strand endonuclease activity.  Finally, we propose that the function of 
WRN in human cells may be to substitute for or aid other helicases and nucleases in the 
processes of DNA replication and/or double-strand break repair.  The action of WRN as 
an important “back-up” system in DNA replication and repair might provide one 
explanation for why the symptoms of WS develop over decades, rather than being 
temporally acute. 
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Table I. DNA Molecules Employed in these Studies 
 
Length        Sequence 
 
Substrate R: 
(1) 24 nt    5’-d (CAGGCACAGGGTCAGGTCGGGGGG) –3’ 
 
(2) 60 nt    5’-d (TCTACGCTCTGAGTGACTGACAAGTTTTTTTTTTTTCCCCCCGA 
                          CCTGACCCTGTGCCTG) –3’  
 
Substrate S: 
(3) 20 nt    5’-d (CGCTAGCAATATTCTGCAGC) –3’ 
 
(4) 46 nt    5’-d (GCGCGGAAGCTTGGCTGCAGAATATTGCTAGCGGGAAATCGG 
                           CGCG) –3’  
 
Substrate L: 
1 kb DNA duplex with 100-base 5’-overhang 
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Table II. Predicted and Observed AFM Volumes for hWRN-N70-240 and PCNA 
Oligomers 
 
Complexes    Molecular Weight  Predicated AFM      Observed AFM 
        (kDa)  Volume (nm3)   Volume (nm3) 
 
Monomer   hWRN-N70-240                 21                            2.3                         not observed   
 
Dimer         hWRN-N70-240                 42                            29.6           not observed 
 
Trimer        hWRN-N70-240            63                            56.9                        68 ± 8 
 
Hexamer     hWRN-N70-240           126                          138.8                      135 ± 7         
 
Monomer   PCNA                        29                            12.7                        not observed 
 
Trimer        PCNA                        87                            88.1                        94 ± 7            
 
Hexamer     PCNA                      174                           201.2                      not observed 
 
Trimer hWRN-N70-240                 150                           170                         150 ± 15  
Trimer PCNA complex    
 
Hexamer hWRN-N70-240              213                          251.9                       235 ± 11   
Trimer PCNA complex   
 
Hexamer hWRN-N70-240              300                          365                          not observed 
Hexamer PCNA complex    
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Figure Legends 
Figure 1: Amino acid sequence alignment of residues 1-360 from the N-terminal regions 
of the human and mouse WRN proteins, generated using Workbench software. Identical 
amino acids are in red, similar amino acids are in blue, and the five amino acids thought 
to be critical for exonuclease activity are in bold.  
 
Figure 2: A: DNA duplex (substrate R) composed of a 32P 5’-labeled (star) 24-mer with a 
recessed 3’-end and an unlabeled 60-mer (see Table I).  B: hWRN-N70-240 and hWRN-N1-
333 exonuclease activities on a DNA substrate with a recessed 3’-end. The lane marked 
“uncut” contains DNA that has not been treated with wither hWRN-N70-240 or hWRN-N1-
333. The times below each lane corresponds to the length of time DNA substrate R was 
incubated with an hWRN-N construct at 37 °C prior to the addition of 0.5 mM EDTA 
and 80% formamide. The nucleolytically fragmented 32P-5’-labeled 24-mer was resolved 
from undigested DNA by electrophoresis through a 20% denaturing polyacrylamide gel 
as described (see Materials and Methods). 
 
Figure 3: Analysis of quaternary structure of hWRN-N70-240 by gel filtration 
chromatography.  A: Elution profile for purified hWRN-N70-240 on a Superdex S-200 
column.  B: Elution of the hWRN-N70-240 oligomers and molecular weight markers from 
Superdex S-200 chromatography. The molecular weight markers are ferritin (440 kDa), 
aldolase (158 kDa), ovalbumin (43 kDa) and ribonuclease A (13.7 kDa). The elution peak 
for dextran from the column was considered the exclusion volume (V0). Vt was 
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determined by the elution of salt from the column. Ve is the elution volume of hWRN-
N70-240 oligomers (closed square) and molecular weight markers (closed circles).  
 
Figure 4: A: AFM image of hWRN-N70-240 at 20 nM. The image shows proper surface 
coverage for volume analysis. hWRN-N70-240  was equilibrated  at 37 °C for 15 min in 20 
mM Tris-HCl, pH 7.8, 30 mM NaCl, 5 mM MgCl2 and 5% glycerol. A deposition time of 
30 seconds was used for this concentration of hWRN-N70-240. The scale bar represents 
200 nm. B: Gaussian fit of the volume histogram for hWRN-N70-240 (20 nM). The solid 
line is the Gaussian fit of the volume data for trimers. The number of proteins under each 
curve represents that species’ population. The number within the parentheses (1135) 
represents the number of proteins analyzed. Only the trimer distribution has a Gaussian 
shape, and the fraction of trimers determined by counting the number of proteins under 
the curve is 83%.  
 
Figure 5: Gaussian fit of the volume histogram for yeast PCNA (yPCNA) and 
yPCNA:hWRN-N70-240 complexes. A: yPCNA (40 nM) alone was equilibrated at 37 °C 
for 15 min in 20 mM Tris-HCl, pH 7.8, 30 mM NaCl, 5 mM MgCl2 and 5% glycerol and 
deposited to freshly cleaved mica for 30 sec. The solid line is a Gaussian fit of the 
volume data for yPCNA trimers. B: yPCNA and hWRN-N70-240 binding in the same 
buffer as yPCNA alone for 15 min at room temperature prior to deposition on mica. Two 
distributions represent trimer yPCNA: trimer hWRN-N70-240 complexes and trimer 
yPCNA: hexamer hWRN-N70-240 complexes. 
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Figure 6: Binding of hWRN-N70-240 to DNA containing a 3’-recessed end. A: Surface 
plot of an enlarged AFM image of hWRN-N70-240–DNA complexes. The scale bar 
represents 100 nm. The DNA substrate S alone is too small to be visualized by AFM (20-
mer:46-mer; 7 nm in length).  Arrows indicate hWRN-N70-240 monomers, trimers and 
hexamers. B: Gaussian fit of the volume histogram for hWRN-N70-240-DNA complexes. 
The solid line is the Gaussian fit of the volume data for trimers and hexamers. The 
number of proteins under the trimer curve is 328, and under the hexamer curve is 360. 
The number within the parentheses (728) is the number of total proteins analyzed. Both 
the trimer and hexamer distributions have Gaussian shapes. The fraction of trimers is 
45%, and that of hexamers is 49%. The predominant hexamer peak is missing in the 
absence of DNA (see Figure 4). C:  AFM image of the 1 kb DNA substrate L with 100 
base 5’-overhang alone.  These molecules measure between 305 nm and 314 nm in 
length, the expected length of a 900 bp DNA duplex assuming 0.33 nm per bp. D: AFM 
image of hWRN-N70-240-DNA complexes formed on the 1 kb substrate L. Bound hWRN-
N70-240 molecules can be seen at one end of several of the DNA duplexes. Volume 
analysis indicated that bound hWRN-N70-240 molecules are hexamers.  E-F: AFM images 
of a small DNA fragments generated by the digestion of DNA substrate L by hWRN-N70-
240. hWRN-N70-240 and substrate L were incubated at 37 °C for 15 minutes in 1 mM ATP 
before deposition on mica. In E, DNA molecules of 301 nm (912 bp), 299 nm (906 bp), 
91 nm (275 bp), 75 nm (227 bp), and 47 nm (142 bp) can been seen.  In F, DNA 
molecules of 289-285 nm (~870 bp), 265 nm (803 bp), 141 nm (427 bp), 112 nm (340 
bp), 82 nm (248 bp), 54 nm (163 bp), and 37 nm (112 bp) can been seen.   The scale for 
both E and F is identical. 
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Figure 7: hWRN-N70-240 endonuclease and exonuclease activities on a 5’-protruding 
DNA strand.  The times below each lane indicate the length of time DNA substrate R, 
which was radiolabeled on 5’-end of the bottom 60 nucleotide strand, and hWRN-N70-240 
were incubated together at 37 °C prior to the addition of 0.5 mM EDTA and 80% 
formamide. The nucleolytically fragmented 32P 5’-labeled 60-mer was resolved from 
undigested DNA by electrophoresis through a 20% denaturing polyacrylamide gel as 
described (see Materials and Methods).  The lane marked “uncut” contains DNA that has 
not been treated with hWRN-N70-240; the position of the 5’-labeled 60-mer is indicated.  
Three “marker” lanes are also present, which contain standards of 36, 24, 12 10, 8, 6, 4, 
3, 2, and 1 nucleotides in length.  The sequence of the DNA substrate R employed in 
these studies is shown; this substrate contains a 24 bp duplex region and a 36 nucleotide 
5’-protruding strand.  The sites of the initial bursts of endonuclease cleavage that 
generate the 36 base and 12 base products are indicated (open arrows).  The position of 
the non-transient endonuclease cleavage that generates the 24 base product is shown 
(closed arrow).  In addition, the sites of 3’-5’ exonuclease cleavage of the 24 base 
product, the clearest single-stranded DNA exonuclease activity present in this gel, are 
also indicated (closed arrowheads). 
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Figure 1 
 
human_WRN_1-360    1 MSEKKLETTAQQRKCPEWMNVQNKRCAVEERKACVRKSVFEDDLPFLEFT 
mouse_WRN_1-360    1 -----METTSLQRKFPEWMSMQSQRCATEEK-ACVQKSVLEDNLPFLEFP 
                                                     
human_WRN_1-360   51 GSIVYSYDASDCSFLSEDISMSLSDGDVVGFDMEWPPLYNRGKLGKVALI 
mouse_WRN_1-360   45 GSIVYSYEASDCSFLSEDISMRLSDGDVVGFDMEWPPIYKPGKRSRVAVI 
 
human_WRN_1-360  101 QLCVSESKCYLFHVSSMSVFPQGLKMLLENKAVKKAGVGIEGDQWKLLRD 
mouse_WRN_1-360   95 QLCVSESKCYLFHISSMSVFPQGLKMLLENKSIKKAGVGIEGDQWKLLRD 
 
human_WRN_1-360  151 FDIKLKNFVELTDVANKKLKCTETWSLNSLVKHLLGKQLLKDKSIRCSNW 
mouse_WRN_1-360  145 FDVKLESFVELTDVANEKLKCAETWSLNGLVKHVLGKQLLKDKSIRCSNW 
 
human_WRN_1-360  201 SKFPLTEDQKLYAATDAYAGFIIYRNLEILDDTVQRFAINKEEEILLSDM 
mouse_WRN_1-360  195 SNFPLTEDQKLYAATDAYAGLIIYQKLGNLGDTAQVFALNKAEENLPLEM 
 
human_WRN_1-360  251 NKQLTSISEEVMDLAKHLPHAFSKLENPRRVSILLKDISENLYSLRRMII 
mouse_WRN_1-360  245 KKQLNSISEEMRDLANRFPVTCRNLETLQRVPVILKSISENLCSLRKVIC 
 
human_WRN_1-360  301 GSTNIETELRPSNNLNLLSFEDSTTGGVQQKQIREHEVLIHVEDETWDPT 
mouse_WRN_1-360  295 GPTNTE-------------------------------------------- 
 
human_WRN_1-360  351 LDHLAKHDGE 
mouse_WRN_1-360      ---------- 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6.                      
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Figure 7. 
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Abstract 
The human nuclear pregnane X receptor (PXR) responds to a wide variety of xenobiotic 
and endobiotic compounds, including pregnanes, progesterones, corticosterones, 
lithocholic acids, and 17β-estradiol.  In response to these ligands, the receptor controls 
the expression of genes central to the metabolism and excretion of potentially harmful 
chemicals from both exogenous and endogenous sources.  While the structural basis of 
PXR’s interaction with small and large xenobiotics has been examined, the detailed 
nature of its binding to endobiotics, including steroid-like ligands, remains unclear.  We 
report the crystal structure of the human PXR ligand binding domain (LBD) in complex 
with 17β-estradiol, a representative steroid ligand, at 2.65 Å resolution.  Estradiol is 
found to occupy only one region of PXR’s expansive ligand binding pocket, leaving a 
notable 1,000 Å3 of space unoccupied, and to bridge between the key polar residues Ser-
247 and Arg-410 in the PXR LBD.  Positioning the steroid scaffold in this way allows it 
to make several direct contacts to αAF of the receptor’s AF-2 region.  The PXR-estradiol 
complex was compared to that of other nuclear receptors, including the estrogen receptor, 
in complexes with analogous ligands.  It was found that PXR’s placement of the steroid is 
remarkably distinct relative to other members of the nuclear receptor superfamily.  Using 
the PXR-estradiol complex as a guide, the binding of other steroid- and cholesterol-like 
molecules was then considered.  The results provide detailed insights into the manner in 
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which human PXR responds to a wide range of endobiotic compounds.
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Introduction 
The pregnane X receptor (PXR; also known as SXR and PAR) plays a central role in 
xenobiotic detection and the subsequent regulation of genes involved in drug metabolism 
and excretion (1-4).  The receptor has also been shown to respond to key endogenous 
ligands, including 5-β-prenane-3,20-dione, progesterones, corticosterones, testosterone, 
prenenolones, lithocholic acids, the steroid-like compound dexamethasone, and 17β-
estradiol (4-11).  Indeed, PXR was termed the pregnane X receptor because it is activated 
by a variety of C21 steroids (4). In response to these and other chemicals, PXR regulates 
the expression of gene products involved in protective cholesterol and bile acid 
metabolism and processing.  PXR is a member of the nuclear receptor (NR) superfamily 
of ligand-regulated transcription factors and, like most NRs, contains both DNA- and 
ligand-binding domains (DBD, LBD, respectively) connected by a presumably flexible 
hinge region(12).  PXR functions as an obligate heterodimer with the retinoid X receptor 
(RXR), and binds to various combinations of direct and everted repeat elements in the 
regulatory regions of target genes (3).  While it does not contain a lengthy activation 
function 1 (AF-1) region at its N-terminus like other NRs, PXR maintains an intact AF-2 
within its LBD, which is stabilized by bound ligand and facilitates the recruitment of 
transcriptional coactivators (13).  Unlike many nuclear receptors, however, PXR exhibits 
a consistent basal transcriptional activity in the absence of ligand (4, 14). 
 
Crystal structures of the PXR LBD have been reported in its apo (unliganded) state, as 
well as with small drug-like and herbal ligands (e.g., SR12813, hyperforin) and the large 
macrolide ligand rifampicin (13-16).  These structures have revealed that PXR contains 
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an expansive and structurally conformable ligand binding pocket capable of changing in 
shape depending on the nature of its bound ligand.  PXR also maintains a ~60-residue 
insert between α1 and α3 in the well-established LBD fold, which adds a variety of 
distinct features to PXR including two β-strands that extends the standard two- to three-
stranded LBD β-sheet to five strands in PXR (17).  The terminal β-strands in these β-
sheets interact in an ideal antiparallel fashion in PXR to form a homodimer unique to 
PXR that has recently been shown to be critical for receptor function (18).  It has also 
been noted that the PXR LBD deviates significantly in sequence across species relatively 
to other NRs, and these differences have lead to the hypothesis that the PXRs evolved to 
respond to xenobiotic or endobiotic pressures distinct to each species (4, 19). 
 
While the nature of PXR’s interactions with xenobiotics has been well examined 
structurally, no corresponding structural data exist to date on the interaction of PXR with 
an endogenous ligand, including steroid-like compounds which appear to be of 
predominant importance.  To address this, we determined the crystal structure of the PXR 
LBD in complex with 17β-estradiol, a representative steroid, and refined it to 2.65 Å 
resolution.  This structure reveals that PXR positions estradiol in one hemisphere of its 
ligand binding pocket, bridging key polar regions of the receptor, and directly contacting 
the AF-2 region.  This binding mode is distinct relative to both the estrogen receptor’s 
interaction with the same ligand (20), and the manner in which other NRs contact steroid- 
or cholesterol-like ligands (21-26).  In addition, the data outlined in this paper supports 
the hypothesis that PXR’s evolution has been significantly impacted by the ability to 
recognize the bile acids unique to different organisms and to play a protective role in 
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eliminating toxic levels of such compounds.  In summary, this structure provides the first 
scaffold by which the binding of endogenous ligands to PXR can be understood and 
probed at the molecular level. 
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Results 
Overall Structure.  To unravel the structural basis of the recognition of endogenous 
steroid-like ligands by the nuclear xenobiotic receptor PXR, we determined the crystal 
structure of the PXR LBD in complex with 17β-estradiol.  Repeated attempts to obtain a 
structure of this complex were hampered by the covalent attachment of the reducing 
agent dithiothreitol (DTT) to Cys-284 within the ligand binding pocket of PXR, as 
visualized within several crystal structures (data not shown).  Thus, this cysteine side 
chain was replaced with serine using PCR mutagenesis, which produced a form of the 
LBD that generated a stable complex with estradiol.  Crystals were obtained, and data 
collected to 2.65 Å resolution at the SER-CAT facility at APS (Argonne, IL).  The 
structure was determined by molecular replacement and refined using torsion angle 
dynamics to Rcryst and Rfree values of 0.217 and 0.273, respectively (Table I).  The PXR 
LBD conformation is similar to that observed in other PXR-ligand complexes determined 
to date (13-16), exhibiting the three alpha-helical layers common to nuclear receptor 
LBDs but with the unique PXR features of an extended β-sheet mediating homodimer 
formation (Figure 1A).    The PXR LBD in the estradiol complex shares 0.5 Å root-mean-
square deviation in Cα atom positions with the apo (unliganded) PXR structure (14), and 
is in the active conformation with regards to its AF-2 surface.  Only a few residues 
adjacent to the ligand binding pocket exhibit small shifts in position between the two 
structures, including Ser-247 (60° rotation, producing a ~1 Å shift), Cys-284-Ser (60° 
rotation, ~2 Å shift), Leu-411 (rotamer change for 2.5 Å shift), Met-243 (rotamer change 
for 1.5 Å shift), and Arg-410 (1 Å shift).  Thus, the binding of estradiol to the PXR LBD 
does not induce large structural changes relative to the unliganded form of the receptor. 
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Estradiol Binding.  The use of |FobsLigand – FobsApo|, φcalc maps to identify clearly the 
positioning of ligands has been effective in past PXR-agonist complex structure 
determinations (16).  Thus, we calculated an |FobsPXR-Est – FobsApo|, φcalc map at 2.8 Å 
resolution; clear electron density at 3σ indicated the position of 17β-estradiol bound 
within the PXR ligand binding pocket (Figure 1B).  It was particularly helpful to observe 
density for the extracyclic 18-methyl group, which allowed for unambiguous placement 
of the ligand in a single orientation.  Estradiol refined with relatively high thermal 
displacment parameters (~85 Å2), although such values have been observed with other 
ligands bound to PXR (e.g., rifampicin) (15). 17β-estradiol forms hydrogen bonds with 
two PXR side chains and additional interactions with eight other residues.  The 3-
hydroxyl group on the steroid A-ring forms a 2.7 Å hydrogen bond with Ser-247, while 
the 17β-hydroxyl group on the D-ring forms a 2.9 Å hydrogen bond with Arg-410 
(Figure 1C). Arg-410 is stabilized by a 2.9 Å hydrogen bond with Ser-208, which itself is 
3.5 Å from the oxygen of the ligand’s 17β-hydroxyl group. Arg-410 is further stabilized 
by a 3.0 Å hydrogen bond with the side chain of Glu-321.  The side chain of His-407 was 
placed in two distinct orientations in this structure, and each orientation forms a 3.3 Å 
van der Waals contact with atoms within the ligand.  Thus, polar interactions appear to 
position the ligand within one region of the ligand binding cavity, which leaves a 
significant portion of the available room within the pocket unoccupied (Figure 1A). 
 
Non-polar contacts also play a key role in stabilizing 17β-estradiol within the ligand 
binding pocket of PXR.  Phe-420 forms a 4.5 Å edge-to-face contact normal to the 
conjugated A-ring of the steroid, while the side chain of Phe-429 forms a second edge-to-
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face contact more parallel to the A-ring at a distance of 3.5 Å (Figure 1C).  The A-ring is 
further stabilized by 3.4 Å and 3.6 Å van der Waals contacts with Leu-411 and Met-425, 
respectively, and by a 3.0 Å interaction between the π-orbitals of Phe-251 and the 3-
hydroxyl group of the steroid.  The B-ring of the steroid is also forms a 3.4 Å van der 
Waals contact with Met-243.  Note that Met-425 and Phe-429, which are directly 
contacted by estradiol, are located on αAF of the PXR AF-2 surface; thus, these 
interactions likely help to stabilize the active AF-2 conformation of the receptor.  The 
volume of the human PXR ligand binding pocket without estradiol present is 1,376 Å3, as 
calculated by the method of CASTp (27).  In the presence of the ligand, however, this 
volume only decreases by 395 Å3, leaving 981 Å3 unoccupied by ligand. 
 
PXR Mutants.  To examine the role that individual residues may play in the activation of 
PXR by steroid-like compounds, single-site mutant forms of the full-length receptor were 
generated.  The activation of a luciferase reporter gene under the control of the 
cytochrome P450-3A4 promoter was examined in CV-1 cells upon treatment with 
increasing concentrations of two established PXR agonists, rifampicin and SR12813 (13-
15), or 17β-estradiol (Figure 2, Table II).  For SR12813 and rifampicin, concentrations 
between 10 nM and 10 µM were examined.  For the weaker agonist estradiol, 
concentrations up to 100 µM were examined so that EC50 values could be calculated 
(Table II); however, in Figure 2, the complete dose-response curve for estradiol is only 
shown for the wild-type form of the receptor.  Wild-type PXR exhibited the moderate 
basal activation levels commonly observed for PXR, and EC50 values of 0.14, 0.70 and 
9.5 µM in response to SR12813, rifampicin, and estradiol, respectively.  The binding 
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affinities of SR12813, rifampicin, and 17β-estradiol to PXR are measured by scintillation 
proximity assays to be 0.05, 5.2 and 5 µM, respectively (data not shown).  Mutating Ser-
247, which hydrogen bonds directly to estradiol, to tryptophan produces a form of the 
receptor that is constitutively active regardless of the presence of agonist.  A bulky indole 
ring in this position likely fills a portion of the ligand binding pocket, and, significantly, 
would be expected to contact directly Met-425 on the receptor’s αAF.  Such an 
interaction would likely stabilize the active conformation of AF-2, leading to reporter 
gene expression.  Recall that in the PXR-estradiol crystal structure, the ligand also 
directly contacts Met-425.  Mutating His-407, which forms van der Waals contacts with 
estradiol, to glutamine does not significantly impact receptor activity, likely because this 
polar side chain is expected to form analogous contacts with ligand.  It is noted that a 
slight increase in basal activation of transcription is observed with His-407-Gln forms of 
full-length PXR; the structural basis of this effect is unclear.  Mutating Arg-410, which 
forms the other direct hydrogen bond with estradiol, with a shorter asparagine side chain 
does not alter the activation of the receptor by ligands.  Asparagine in this position is still 
capable of forming a hydrogen bond with the 17-hydroxyl group of estradiol.  This 
mutation does eliminate basal, ligand-independent activation of PXR, however.  The 
likely explanation for this effect is that an Arg-410-Asn residue would not be capable for 
forming a salt bridge with Glu-321. Taken together, these mutations indicate that polar 
interactions formed between PXR and estradiol play an important role in activation of the 
receptor by this steroid ligand. 
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Estradiol Binding by PXR vs. ER.  We next sought to compare structurally the binding of 
estradiol by PXR in relation to the interaction of this steroid hormone to its cognate 
receptor, the estrogen receptor, another member of the nuclear receptor superfamily.  The 
crystal structure of PXR in complex with 17β-estradiol shares 2.6 Å rmsd over Cα 
positions with the structure of the estrogen receptor-α (ERα) (20), and the two LBDs 
share 16% sequence identity.  A superposition of the LBDs reveal that, while the overall 
folds of the proteins are similar, the positions of the bound ligands within the pockets are 
distinct (Figure 3A).  Estradiol in PXR binds closely adjacent to αAF and leaves a 
portion of the large ligand binding pocket in this receptor unoccupied.  In contrast, 
estradiol is more centrally located in the ERα pocket, is oriented nearly perpendicular to 
that observed in the PXR complex, and occupies all but ~56 Å3 of the space in the central 
pocket. ERα forms three hydrogen bonding and twelve non-polar contacts with estradiol, 
while PXR forms only two hydrogen bonds and eight van der Waals interactions (Table 
III).  The 3-hydroxyl group on the A-ring of the steroid forms two hydrogen bonds in the 
ERα complex, with Glu-353 and Arg-394; in PXR, these residues are replaced with the 
hydrophobic residues Met-250 and Val-291, respectively (Figure 3B).  The A-ring is 
further contacted in ERα by an edge-to-face interaction with Phe-404, which is replaced 
by Cys-301 in PXR.  Thus, contacts analogous to those observed between ERα and the 
A-ring of estradiol are not possible in PXR. ERα forms a hydrogen bond between His-
524 and the 17-hydroxyl group in estradiol; His-524 is replaced by Arg-410 in PXR, 
which a similar interaction in the PXR-estradiol complex.  The D-ring is further 
contacted by Met-421 in ERα, which is equivalent to Ser-208 in PXR.  In summary, only 
one of three hydrogen bonds formed by ERα with estradiol is conserved in PXR, and 
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only three of twelve van der Waals contacts are maintained (Table III).  Indeed, key 
residues involved in PXR’s contact with estradiol are replaced by significantly different 
side chains in ERα as well.  For example, the PXR residues Ser-247, His-407, Phe-420, 
Phe-429 and Phe-251 are equivalent to alanine, glycine, valine, and two leucine residues, 
respectively, that do not form analogous contacts in ERα (Figure 3B; Table III).  
Significantly, however, both complexes with estradiol reveal that direct contacts are 
formed between the ligand and amino acid side chains on the αAF helices within the AF-
2 region (Met-425 in PXR, Leu-540 in ERα), providing a molecular explanation for the 
ability of these agonists to facilitate gene activation by the receptors.   
 
Insights into PXR Activation by Other Endogenous Ligands.  PXR is well established as 
both a xenobiotic and endobiotic sensor.  Endogenous ligands known to activate human 
PXR-mediated gene expression include pregnanes, progesterone, corticosterone, 
testosterone, lithocholic acids, and the steroid-like xenobiotic dexamethasone (1, 4, 5, 7-
9, 11).  We next sought to examine the basis of PXR activation by endogenous 
compounds by using as a guide the PXR-estradiol structure, the first determined for a 
steroid scaffold ligand in complex with this receptor.  As summarized above, estradiol 
bridges between two polar regions within the PXR pocket, represented by Ser-247 and 
Arg-410 (Figure 4).  Arg-410 is also proximal to the surface of the receptor, and to a 
series of other polar side chains that are either adjacent to (e.g., Ser-206 at 3.5 Å) or more 
distant from estradiol, such as Arg-413, Asp-205, Lys-204, and Asp-230 (Figure 4).  
Using binding modes analogous to estradiol as a guide, a series of endogenous 
compounds that are known PXR activators were modeled into the receptor’s ligand 
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binding pocket.  Significantly, all compounds capable of maintaining contacts to Ser-247 
and the Arg-410 regions were established PXR agonists.  For example, 5-β-pregnane-
3,20-dione, a ligand for which PXR (the pregnane-X-receptor) is named (4), is capable of 
forming hydrogen bonds with both Ser-247 and Arg-410.  Indeed, particular ligands with 
3-keto groups, regardless of the conjugated state of their A-rings, appeared capable of 
receiving hydrogen bonds from Ser-247 (Figure 4).  In the cases of corticosterone, 
cortisol, 3-keto-lithocholic acid, and 3-keto-7α,12α-dihydroxy-5α-cholanic acid, 
additional favorable contacts were also likely.  For example, the polar side chain of His-
407 appeared ideally positioned to interact with hydroxyl or keto oxygens at either the 11 
or 12 positions on the steroid scaffolds (see corticosterone, cortisol, and 3-keto-7α,12α-
dihydroxy-5α-cholanic acid in Figure 4).  In addition, extended side chains at the 17 
positions of the steroid are also observed to make favorable contacts with polar residues 
adjacent to Arg-410, such as those shown for dexamethasone-t-butylacetate and 3-keto-
7α,12α-dihydroxy-5α-cholanic acid.  3-β-acetate moieties were also found to be capable 
of forming polar interactions with Ser-247, which explains the activation of PXR by 
lithocholic acid acetate and lithocholic acid acetate methyl ester (Figure 4). Similarly, 3-
β- and 3-α-hydroxyl groups appeared appropriately positioned to hydrogen bond to Ser-
247, helping to explain the agonist character of prenenolones and DHEA (Figure 4).  
Certain bile acids identified as activators of human PXR were also found to be capable of 
spanning the distance between Ser-247 and the polar residues adjacent to Arg-410, 
including glycolithocholic acid and taurolithocholic acid.  Taken together, the data 
presented here provide a structural framework in which endogenous, steroid-like 
molecules may be understood at the molecular level to be ligands for human PXR. 
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Discussion 
The human PXR LBD, which has been shown to respond to a variety of both endogenous 
and xenobiotic compounds, shares structural similarity with the NR superfamily LBDs 
(28), including that of ER.   However, in this report, we show that PXR binds to ER’s 
endogenous ligand, 17β-estradiol, in a manner markedly distinct from the estrogen 
receptor.  While estradiol fills the ligand binding pocket of ER, it binds adjacent to the 
αAF of the AF-2 region in PXR, leaving a significant portion of PXR’s large binding 
pocket unoccupied.  Several structural features within each receptor lead to this 
difference in binding orientation.  The central β-strand (β2) in ER’s three-stranded β-
sheet is dips deeper into the ligand binding pocket in this receptor relative to PXR, and 
positions Phe-404 such that it can form an edge-to-face contact with the bound estradiol 
molecule (20).  ER also contains a longer α6 and no equivalent to the α2 and β1/ β1’ 
secondary structural elements of PXR; together, these features allow ER to place a large 
number of side chains snugly within the ligand binding pocket to contact estradiol.  In 
addition, while PXR’s pocket is more expansive than that of ER, key estradiol-contacting 
residues in ER are replaced in PXR.  For example, Glu-353 and Arg-394 of ER 
correspond to Met-250 and Val-291 in PXR, respectively, neither of which is capable of 
forming central polar contacts to the steroid ligand.  Phe-288 and His-407 in PXR, which 
replace Leu-391 and Gly-521 in ER, respectively, would also clash at ~1 Å from estradiol 
bound as it is observed in ERα.  Taken together, these observations indicate that key 
structural differences in the LBD folds of ER and PXR allows these two NRs to bind 
17β-estradiol in remarkably distinct manners, revealing the plasticity present in the 
common NR fold. 
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Several other nuclear receptors bind to steroid-like ligands, including the glucocorticoid 
receptor (GR), the liver X receptor (LXR) and the constitutive androstane receptor 
(CAR).  We compared the PXR-estradiol complex structure with those of GR-
dexamethasone (21), LXR-25-epoxycholesterol (25) and CAR-5β-pregnane-3,20-dione 
(26) (Figure 5).  Similar to ER-estradiol, the GR and LXR complexes reveal that the 
steroid ligand is bound nearly perpendicular to that observed in PXR.  The contacts 
leading to these binding modes are similar to that described above for ERα, including the 
packing of several side chains into the ligand binding pockets of GR and LXR to generate 
receptor-ligand interactions.  Recall that GR and LXR are both highly specific for 
steroid-like ligands, whereas PXR exhibits a much broader ligand-binding profile.  In this 
respect, it was interesting to observe that CAR, another receptor that responds somewhat 
promiscuously to ligands, positions 5β-pregnane-3,20-dione in a manner somewhat 
similar to the placement of estradiol in PXR.  However, in CAR, 5β-pregnane-3,20-dione 
does not directly contact αAF of the receptor’s AF-2 domain; instead, Asn-165 and Tyr-
326, which interact with the ligand, mediate contacts to αAF.  In PXR, these residues are 
replaced by Ser-247 and His-407, respectively, which form both key interactions with 
estradiol and also facilitate the positioning of the ligand in direct contact with αAF.  It is 
expected that CAR would not respond to estradiol because the planar A-ring of this 
steroid ligand would clash with aromatic side chains within the CAR binding pocket (26).  
The farnesoid X receptor (FXR), which responds to bile acids, was shown previously to 
orient 6-ethyl-chenodeoxylchlolic acid similar to that observed for dexamethasone bound 
GR, with the distinction that the A-ring faces the opposite direction in FXR (22).  Again, 
this position is distinct relative to the observed estradiol docking adjacent to αAF in the 
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PXR complex presented here; indeed, the position of the loop after α1 in PXR, which 
deviates by up to 9 Å relative to the same region in FXR, makes the analogous interaction 
of bile acids to PXR impossible (not shown).  Taken together, these observations 
highlight the distinct nature of PXR’s interaction with steroid-like ligands relative to 
other members of the NR superfamily. 
 
It has been proposed that bile acids played a key role in driving the evolution of the PXRs 
in a variety of organisms (8).  Indeed, PXR has been shown to respond to toxic levels of 
bile acids and to coordinate the expression of protective gene products capable of 
metabolizing and excreting bile acids that may accumulate in hepatocytes (5, 29-38). 
Schuetz and colleagues recently examined the activation by bile acids of a wide variety of 
PXRs and PXR-like receptors, including those from human, mouse, rat, dog, cow, pig, 
rhesus, rabbit, chicken (CXR), the zebrafish PXR, and Xenopus BXR, a benzoate 
receptor (8).  They concluded that, in terms of responses to endogenous bile acids present 
in each organism, the receptors could be grouped in the following fashion: human; dog, 
pig, rhesus (and, likely, cow); mouse and rat; rabbit; CXR; BXR; zebrafish PXR.  Using 
the human PXR-estradiol complex as a guide, we examined the conservation of key 
residues in the human PXR ligand binding across these orthologous receptors (Table IV).  
We found that as the receptors deviate in their responses to distinct bile acids, the 
conservation of central residues within the binding pocket clearly diminishes. Thus, our 
structural data support the conclusion that differences in the nature of endogenous bile 
acids may have played a significant role in the evolution of the PXRs and PXR-like 
receptors in a wide variety of organisms. 
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In summary, the data presented here reveals that PXR interacts with the steroid-like 
molecules by positioning them such that they contact Ser-247, Arg-410, and αAF of the 
receptor’s AF-2 surface.  As noted in Figure 2, PXR has a relatively robust basal 
activation level, which is then significantly enhanced in the presence of ligands.  The 
binding of a ligand like estradiol with a moderate EC50 in close proximity to the AF-2 
surface likely allows PXR to enhance transcriptional activation without the need for high 
ligand binding affinity.  The placement of steroid-scaffold in PXR is distinct relative to 
other nuclear receptor-steroid interactions, including that of GR, LXR and the CAR 
receptor, which shares some overlapping biological functions with PXR.  This structure 
provides a framework by which the interactions of other endogenous steroid- and 
cholesterol-like molecules can be understood, and their potential physiological roles 
probed both in vitro and in vivo.   
   106 
Materials and Methods  
Protein Expression and Purification. The PXR LBD expression construct was engineered 
as an N-terminal polyhistidine tagged fusion protein with residues 130-434 from the 
human PXR.  The fusion insert was subcloned into the pRSETA expression vector 
(Invitrogen).  Cys-284 within the PXR ligand binding pocket was mutated to serine, to 
prevent oxidation with DTT during crystallization, using the QuikChange mutagenesis kit 
(Stratagene, La Jolla, CA) according to the manufacturer’s instructions.  The mutant was 
confirmed by sequence analysis.  Residues 623-710 of the human SRC-1 gene were 
subcloned into the bacterial vector pACYC184 along with a T7 promoter (39).  The PXR 
LBD/pRSETA and the SRC-1/pACYC184 plasmids were co-transformed into the 
BL21(DE3) strain of E. coli.  Ten-liter shake flask liquid cultures containing standard 
Luria-Bertani (LB) broth with 0.1 mg/ml ampicillin and 0.034 mg/ml chloramphenicol 
were inoculated and grown at 22 oC for 20 hours.  The cells were harvested by 
centrifugation (20 minutes, 3500 g, 4 oC) and the cell pellet was stored at -80oC.  The cell 
pellet was resuspended in 100 ml Buffer A (50 mM Tris-Cl pH7.8, 250 mM NaCl, 50 
mM Imidazole pH7.5, 5% glycerol).  Cells were sonicated for 3-5 minutes on ice and the 
cell debris was removed by centrifugation (90 minutes, 20,000g, 4 oC).  The cleared 
supernatant was loaded on to a 50 ml ProBond nickel-chelating resin (Invitrogen).  After 
washing to baseline with Buffer A, the column was washed with Buffer B containing 75 
mM imidazole pH 7.5 and Buffer C containing 75 mM imidazole pH 7.5 and 50 mM 
NaCl. The PXR LBD/SRC-1 complex was eluted from the column using Buffer D with 
250 mM imidazole pH 7.5 and NaCl 50 mM.  Column fractions were pooled and 
subjected to SP cation exchange column (BioRad) pre-equilibrated with buffer containing 
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20mM Tris-Cl pH 7.8, 50 mM NaCl, 5 mM DTT, 2.5 mM EDTA pH 8.0, 5% glycerol.  
The column was washed to baseline with the same buffer and fractions containing the 
PXR/SRC-1 complex were eluted at 400 mM NaCl and pooled and diluted two fold with 
the dilution buffer (20 mM Tris-Cl pH 7.8, 5mM DTT, 2.5mM EDTA pH 8.0, 5% 
glycerol). The protein was concentrated using Centri-prep 30K (Amicon) units.  
 
Crystallization. The human PXR ligand-binding domain/SRC-1 complex (hPXR-
LBD/SRC-1) was concentrated in the presence of 100-fold molar excesses of 17 β-
Estradiol to a final concentration of 4 mg/mL. Crystallization was achieved by hanging-
drop vapor diffusion against the following conditions at 22oC: 50 mM imidazole at pH 
7.1, 10% 2-propanol, v/v. 
 
Data Collection and Structure Determination. The structure of the Estradiol-bound form 
of the ligand binding domain of human PXR was determined by molecular replacement 
using the crystal structure of the apo (unliganded) PXR as a search model (14).  Rotation 
and translation function searches were performed using AMoRe (40); clear solutions for 
each were obtained in the proper space group, P43212. The structure was refined using the 
torsion angle protocol in CNS with the maximum likelihood function as a target, and 
included an overall anisotropic B-factor and a bulk solvent correction (41). 10% of the 
observed data were set aside for cross-validation using the free-R statistic prior to any 
structural refinement (42).  Manual adjustments and rebuilding of the model were 
performed using O (43) and σA-weighted electron density maps (44). The structure 
exhibits good geometry (Table I) with no Ramachandran outliers.  
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Transient Transfections. Mutant forms of full-length PXR were generated using the 
QuikChange mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s 
instructions.  All mutants were confirmed by sequence analysis. Transient transfection 
and reporter gene assays were performed as described previously (14-16).  CV-1 cells 
were plated in 96-well plates in phenol red-free Dulbecco’s modified Eagle’s medium 
containing high glucose and supplemented with 10% charcoal/dextran treated fetal 
bovine serum (HyClone, Logan, UT).  Transfection mixes contained 5 ng of receptor 
expression vector, 20 ng of reporter plasmid, 12 ng of β-actin SPAP as internal control, 
and 43 ng of carrier plasmid.  Plasmids for wild-type and mutant forms of human PXR 
and for the XREM-CYP3A4-LUC reporter, containing the enhancer and promoter of the 
CYP3A4 gene driving Luciferase expression, were as previously described (14-16). 
Transfections were performed with LipofectAMINE (Life Technologies, Inc., Grand 
Island, NY) essentially according to the manufacturer’s instructions.  Drug dilutions of 
estradiol (Sigma, St. Louis, MO) and SR12813 (synthesized in-house) were prepared in 
phenol red-free Dulbecco’s modified Eagle’s medium/F-12 medium with 15 mM HEPES 
supplemented with 10% charcoal-stripped, delipidated calf serum (Sigma, St. Louis, MO) 
which had previously been heat-inactivated at 62 °C for 35 minutes.  Serial drug dilutions 
were performed in triplicate to generate 11-point concentration response curves.  Cells 
were incubated for 24 hours in the presence of drugs, after which the medium was 
sampled and assayed for alkaline phosphatase activity.  Luciferase reporter activity was 
measured using the LucLite assay system (Packard Instrument Co., Meriden, CT) and 
normalized to alkaline phosphatase activity.  EC50 values were determined by standard 
methods. 
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Table I.  Crystallographic Statistics for the PXR-Estradiol Complex 
 
 
Resolution (Å; highest shell) 50-2.65 Å (2.74-2.65) 
Space Group P43212 
Asymmetric Unit one molecule 
Cell Constants (Å, °) 
 
 
 
Data collection facilities 
a = b = 90.9 
c = 84.8 
α =  β = γ = 90 
 
APS, SER-CAT 
Total Reflections 
Unique Reflections 
145,600 
10,736 
Mean Redundancy 13.4 (9.5) 
Rsym∗ (%; highest shell) 
Wilson B factor (A2) 
7.0 (21.9) 
50.1 
Completeness (%; highest shell) 
Mean I/σ (highest shell) 
99.2 (96.7) 
37.3 (5.0) 
  
Rcryst† (highest shell) 21.7 (25.6) 
Rfree‡  (highest shell) 27.3 (35.4) 
                                                 
∗
 Rsym = Σ|I-<I>| / ΣI, where I is the observed intensity and <I> is the average intensity of multiple 
symmetry-related observations of that reflection.  
†
 Rcryst = Σ||Fobs|-|Fcalc|| / Σ|Fobs|, where Fobs and Fcalc are the observed and calculated structure factors, 
respectively. 
‡
 Rfree = Σ||Fobs|-|Fcalc|| / Σ|Fobs| for 10% of the data not used at any stage of structural refinement. 
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Table II.  EC50 Values for Activation by Rifampicin or 17β-Estradiol. 
 
 
Full-length PXR Rifampicin 17β-Estradiol 
Wild-Type 1.2 ± 0.22 µM 22 ± 3.2 µM 
Ser-208-Ala 0.58 ± 0.24 µM 15 ± 6.1 µM 
Ser-247-Ala 0.56 ± 0.33 µM >100 µM 
Cys-284-Ser 0.95 ± 0.48 µM 14 ± 7.1 µM 
Arg-410-Leu 2.3 ± 1.1 µM 15 ± 4.5 µM 
Met-425-Ala +  
Phe-429-Ala 
N.A.* N.A.* 
 
 
*The Met-425-Ala + Phe-429-Ala variant of full-length PXR exhibited no response to 
ligands (see Figure 2); thus, no EC50 values were calculated for this form of the receptor.
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Table III.  Comparison of Amino Acids Lining the PXR and ERα Ligand Binding 
Pockets.  Residues listed in bold make polar contacts with 17β-estradiol, while those in 
parentheses are proximal to the binding pocket but are not observed to contact the ligand. 
 
 
PXR Residues Equivalent ERα Residues 
(Ser-208) Met-421 
Met-243 Leu-346 
Ser-247 Ala-350 
(Met-250) Glu-353 
Phe-251 (Leu-354) 
(Ala-280) Trp-383 
(Phe-281) Leu-384 
(Gln-285) Met-388 
Phe-288 Leu-391 
(Val-291) Arg-394 
Glu-321 (Asp-426) 
(Met-323) Leu-428 
His-407 (Gly-521) 
Arg-410 His-524 
Leu-411 Leu-525 
Phe-420 (Val-534) 
Met-425 Leu-540 
Phe-429 (Leu-544) 
(Cys-301) Phe-404 
None1 Ile-424 
 
 
 
1
α7 in PXR is one turn shorter at its N-terminus relative to the equivalent helix in ERα; 
thus, no analogous residue exists in PXR. 
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Table IV.  Comparison of Ligand-Binding Pocket Amino Acids Among NRs Related 
to PXR.  Residues in bold are important in contacting 17β-estradiol in the human PXR-
estradiol complex reported here.  Underlined residues represent a moderate changes, 
while highlighted residues represent major changes, relative to PXRs isoforms close in 
function to human PXR.  “WY” in the last row corresponds to W223 and Y225, which 
residue on the sequence insert novel to isoforms close to human PXR and have been 
shown to be critical to formation of the PXR homodimer and to PXR function. 
 
 
Residue 
(Human) 
Human Pig Cow Rhesus Dog Rabbit Mouse Rat CXR BXR Zebrafish 
205 D D D D D E D D -- -- S 
208 S S S S S T P P S -- S 
243 M I I M M L L L F I F 
247 S S S S S S S S S V T 
251 F F F F F F F F I I I 
281 F F F F F L F F L A F 
321 E Q E E E D D D E E D 
407 H H H H H H Q Q N H Y 
410 R R Q R K R Q Q Q Q Q 
411 L L L L L L L L I L V 
413 R R R R R R R R H E K 
420 F F F F F F F F M D E 
425 M M M M M M M M L M W 
WY WY WY WY WY QY WY WY WY -- -Q DE 
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Figure Legends 
Figure 1.  A.  Crystal structure of the ligand binding domain of human PXR (PXR LBD, 
in red, green, grey) in complex with 17β-estradiol (cyan).  Note the proximity of the 
estradiol ligand to αAF in the activation function-2 (AF-2) region of PXR. 
B.  Electron density from an |FobsPXR-Est – FobsApo|, φcalc map at 2.8 Å resolution and 
contoured at 3σ for 17β-estradiol within the ligand binding pocket of PXR. 
C. 17β-estradiol forms hydrogen bonds with Ser-247 and Arg-410 (bold labels) in the 
PXR ligand binding pocket, as well as van der Waals contacts with several addition 
residues.  The side chain of Arg-410 is also stabilized by a hydrogen bond with Ser-208.  
Note that the ligand contacts two residues, Met-425 and Phe-429 (labeled in red), located 
on αAF of the PXR AF-2 surface. The view in this figure is nearly normal to the plane of 
the estrogen ring system, and rotated roughly 90° about the vertical axis relative to Figure 
1A. 
 
Figure 2.  Transient transfections in CV-1 cells of wild-type (WT) and mutant forms of 
full-length PXR.  Responses of each form of the receptor to SR12813, rifampicin and 
17β-estradiol were measured.  Dose responses for estradiol up to 100 µM were measured 
for all forms of the receptor, but are shown here only for WT PXR. 
 
Figure 3.  A.  Superposition of the ligand binding domains of PXR (red) and the estrogen 
receptor-α (ERα, green) in complexes with 17β-estradiol (cyan, yellow, respectively), 
viewed in the same orientation as Figure 1A. 
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B.  Stereoview of ligand binding pockets of PXR and ERα (red, green, respectively) and 
the interactions they make with 17β-estradiol (cyan, yellow, respectively).  The view is 
the same as that in Figure 3A. 
 
Figure 4.  Analysis of the potential interactions between PXR and other endogenous 
ligands (as well as dexamethasone) predicted by the PXR-estradiol complex reported 
here.  A schematic view of the proximity of key side chains adjacent to estradiol is shown 
at top (S247, R410, S208), along with several residues near the 17-OH moiety.  Known 
PXR agonists with 3-keto, 3-β-acetate, 3-β-hydroxy, and 3-α-hydroxy groups are all 
predicted to form favorable interactions with S247; as shown, further favorable 
interactions may be formed with additional PXR residues, including H407, R413, D205, 
and K204. 
 
Figure 5.  Superpositions of the PXR-Estradiol structure on that of the GR-
Dexamethasone (DEX) complex (top), the LXR-25-epoxycholesterol (eChol) complex 
(middle), and the CAR-5β-pregnane-3,20-dione (pregnane) complex (bottom).  The view 
is the same as that shown in Figure 4, and focusing on the ligand-binding pockets of the 
receptors.
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Figure 1A.   
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Figure 1B. 
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Figure 1C. 
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Figure 2. 
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Figure 3A. 
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Figure 3B. 
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Abstract 
 
The human pregnane X receptor (PXR) recognizes a range of structurally- and 
chemically-distinct ligands and plays a key role in regulating the expression of protective 
gene products involved in the metabolism and excretion of potentially harmful 
compounds.  The identification and development of PXR antagonists is desirable as a 
potential way to control the up-regulation of drug metabolism pathways during the 
therapeutic treatment of disease.  We present the 2.8 Å resolution crystal structure of the 
PXR ligand binding domain (LBD) in complex with T0901317 (T1317), which is also an 
agonist of another member of the orphan class of the nuclear receptor superfamily, the 
liver X receptor (LXR).  In spite of differences in the size and shape of the receptors’ 
ligand binding pockets, key interactions with this ligand are conserved between human 
PXR and human LXR.  Based on the PXR-T1317 structure, analogues of T1317 were 
generated with the goal of designing an PXR antagonist effective via the receptor’s 
ligand binding pocket.  We find that selectivity in activating PXR vs. LXR was achieved; 
such compounds may be useful in addressing neurodegenerative diseases like  
Niemann-Pick C.  We were not successful, however, in producing a PXR antagonist.  
Based on these observations, we conclude that the generation of PXR antagonists 
   129 
targeted to the ligand binding pocket may be difficult due to the promiscuity and 
structural conformability of this xenobiotic sensor.
   130 
Introduction 
The human pregnane X receptor (PXR; alternatively SXR, PAR) responds to a variety of 
endogenous and exogenous compounds in liver, intestine and other tissues, and is a key 
regulator of the expression of genes central to xenobiotic metabolism and excretion (1, 2, 
3).  PXR is also responsible for an important class of drug interactions caused by the 
efficient up-regulation of chemoprotective pathways that lead to the elimination of a wide 
range of therapeutics (4, 5, 6, 7).  It has also recently been shown that T0901317 (T1317), 
the ligand described here in complex with PXR, protects against the development of the 
neurodegenerative disease Niemann-Pick C in a PXR-dependent fashion within a mouse 
model of this condition (8). 
 
Like other members of the orphan class of the nuclear receptor (NR) superfamily, PXR 
contains DNA-binding and ligand-binding domains (DBD, LBD, respectively), acts as a 
heterodimer with the retinoid X receptor-α (RXRα), and binds to a range of direct- and 
everted-repeat elements in the regulatory region of target genes (9).  Upon association 
with an activating agonist, a transcriptional coactivator protein like the steroid receptor 
coactivator-1 (SRC-1) is recruited to the activation function-2 (AF-2) region of the PXR 
LBD, which facilitates changes in chromatin structure and activation of the basal 
transcriptional machinery.  A leucine-rich LxxLL motif in transcriptional coactivators 
(where x is any amino acid) has been shown to interact with a groove present in the 
active orientation of NR LBDs (10, 11).  Crystal structures of the human PXR LBD have 
been determined in complexes with a variety of small (e.g., SR12813, hyperforin) and 
large (e.g., rifampicin) ligands, and with fragments of the human transcriptional 
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coactivator SRC-1 (12, 13, 14, 15).  These structures have revealed that PXR’s ligand 
binding promiscuity is a function of its large and conformable ligand binding pocket, 
which is framed in part by sequence elements novel to PXR relative to other NR LBDs.  
In addition, the PXR LBD forms a unique homodimer mediated by a tryptophan zipper-
like motif, and it has been shown that this interface plays a role in receptor function and 
association with coactivators (16). 
 
The liver X receptor (LXR), another member of the orphan class of NRs that functions as 
a heterodimer with RXRα, plays an important role in monitoring the levels of oxysterols 
in hepatocytes and regulates the expression of genes essential for cholesterol homeostasis 
(17, 18, 19, 20, 21).  The LBDs of the two LXR isoforms, α and β, both share 31% 
sequence identity with the human PXR LBD (and 77% with one another), as well as the 
conserved overall structural fold common to NR ligand binding domains (22, 23, 24, 25, 
26).  The PXR LBD deviates from that of LXR in its ~60-residue α1- α3 insert that adds 
one helix (α2) and two strands (β1, β1’) and frame a significantly larger ligand binding 
pocket relative to LXR (10).  The synthetic NR ligand T0901317 (T1317) is an 
established agonist for LXR, exhibiting robust upregulation of target gene expression 
(19).  The structural basis of T1317 binding to LXR isoform β has been elucidated 
previously (22, 24, 26). 
 
In addition to their association with transcriptional coactivators, NR LBDs bind to 
transcriptional corepressors (e.g., NCoR, SMRT) that exert opposite effects on gene 
transcription by mechanisms that include enhancing the condensed structure of chromatin 
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(4).  Interactions between NRs and corepressors can occur in the absence of ligand, but 
are enhanced in the presence of antagonizing ligands.  A paradigm for this effect is 
provided by efficient down-regulation of transcription caused by the association of the 
estrogen receptor (ER) with the established antagonist tamoxifen.  It has been shown 
structurally that corepressors contain an extended leucine-rich region that binds to an 
inactive LBD conformation distinct in structure from that of an active LBD, particularly 
in the position of the terminal α-helix in the LBD fold (αAF in PXR) (27).  In ER, 
tamoxifen sterically blocks the active orientation of the terminal helix in that fold, 
producing a state that preferentially binds to transcriptional corepressors and down-
regulates gene expression (28).  In the case of PXR, most ligands are found to act as 
agonists of this receptor, in line with its established role in protecting tissues from 
potentially harmful chemicals.  A small number of antagonists have been described, 
however, including the ET-743 (29) and the antifungal ketoconazole (30, 31).  Indeed, 
ketoconazole has been shown recently to repress the binding of both transcriptional 
coactivators and corepressors to PXR (30).  The structural basis of the antagonism of 
PXR by these compounds has not been established, however. 
 
The identification or design of new antagonists of human PXR are desirable because of 
the important role this receptor plays in drug metabolism, and because the current 
antagonists exhibit weak EC50 values relative to established agonists (29, 30, 31).  
Repressing the ability of PXR to recognize the presence of therapeutic compounds may 
allow lower doses to be administered with higher efficacy and fewer side effects.  Here 
we present the 2.8 Å resolution crystal structure of the PXR LBD in complex with 
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T1317.  Using this structure as a guide, and inspired by selective ER modulators 
produced from ER agonists, we generate T1317 analogues designed to act as PXR 
antagonists by disrupting the active conformation of the receptor’s αAF.  We find, 
however, that compounds based on this scaffold either retain their ability to bind to PXR, 
and thus serve as agonists, or simply do not bind to the receptor.  We conclude that the 
design of effective pocket-targeted PXR antagonists may be difficult due to the 
promiscuous and conformable nature of the receptor’s ligand binding pocket. 
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Results 
PXR-T1317 Structure. Crystals of the human PXR LBD were grown in the presence of 
10-fold molar excess T0901317 (T1317), x-ray diffraction data to 2.8 Å resolution were 
collected, and the structure was determined and refined to R and Rfree values of 0.216 and 
0.279, respectively (Table I).  Two ternary complexes were observed in the asymmetric 
unit, each containing one human PXR LBD, one orientation of bound T1317, and one 
fifteen amino acid stretch of the human transcriptional coactivator steroid receptor 
coactivator 1 (SRC-1, residues 682-696) (Figure 1).  The PXR LBD is expressed with an 
88-amino acid fragment of SRC-1 (residue 623-710) to improve protein stability. This is 
the first structure of PXR in which the coactivator fragment remains attached during 
crystallization.  The retention of this fragment is likely due to the relatively high affinity 
and potent agonist activity of T1317.  The 88-amino acid region of human SRC-1 
employed contains two leucine-rich NR box motifs (at 633-637, LVQLL, and 690-694. 
LHRLL).  Only the second NR box was observed associated with the AF-2 region of the 
PXR LBD in both molecules in the crystallographic asymmetric unit.  This implies that 
the sequence around or including LHRLL may have higher affinity for PXR relative to 
the region around the LVQLL motif. 
 
The PXR LBD in this T1317 complex retains the same overall structure observed in 
previous PXR structures, sharing, for example, 1 Å root-mean-square deviation (rmsd) 
over Cα positions with the structure of the apo (unliganded) PXR LBD (15).  The LBDs 
also form a homodimer consistently observed either via crystallographic or, as in this 
case, non-crystallographic symmetry.  This homodimer interaction is mediated largely by 
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interdigitating aromatic residues from β1’ in each monomer, and its formation has been 
shown to be central to transcriptional activity and coactivator recruitment by PXR (16).  
Only a small number of shifts in the positions of amino acids that line the ligand binding 
pocket of PXR were observed between the T1317 and apo structures.  For example, Leu-
209 and Met-323 undergo a rotamer changes and shifts in position of 6.0 Å.  It was also 
noted that the side chains of both His-407 and Phe-429 shift 1.0 Å toward the bound 
ligand relative to the apo structure, and in doing so form a 3.8 Å aromatic edge-to-edge 
van der Waals contact (compared to 5.3 Å for the same atoms in the apo structure).  
Because Phe-429 is located on the αAF of the PXR’s AF-2 region, this interaction likely 
stabilizes the active form of the receptor during the upregulation of gene transcription. 
 
PXR-T1317 Interactions.  T1317 forms three polar and twelve van der Waals contacts 
with amino acid side chains that line the PXR ligand binding pocket (Figure 2; Table II).   
His-407 is positioned 2.4 Å from the ligand’s hydroxyl group, while the polar groups of 
the Gln-285 side chain are 2.9 and 3.2 Å from one sulfoxy oxygen and His-327 is 3.3 
Å from the other.  This is the first time His-327 has been observed within hydrogen 
bonding distance (generously defined) of a bound ligand in any of the PXR complexes 
determined to date.  Similarly, Tyr-306, which forms an edge-to-face with the free benzyl 
ring of T1317, has also not been observed to contact ligand in previous structures.  The 
same T1317 benzyl ring forms parallel and edge-to-face aromatic stacking interactions 
with Phe-288 and Trp-299, respectively.  The two CF3 groups of the ligand form van der 
Waals contacts with five residues, including a 3.5 Å interaction with Met-425 located on 
the receptor’s αAF that likely helps to stabilize the active conformation of the AF-2 
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surface.  The volume of the PXR ligand binding pocket in this structure was measured to 
be 1,334 Å3 and it was further found that the T1317 ligand occupied all but 442 Å3 of that 
space.  In total, the fifteen residues contacted by T1317 is the largest observed for a small 
ligand in PXR’s pocket, but does not exceed the eighteen residues contacted by the large 
macrolide antibiotic rifampicin (12). 
 
T1317 Binding by LXR vs. PXR.  We next compared the structure of the human PXR 
LBD-T1317 complex to that of the human LXRβ LBD complexed to the same ligand 
(22, 24, 25, 26).  The LBDs exhibited the same overall fold, sharing 2.2 Å rmsd over Cα 
positions (and 27% sequence identity), although the secondary structural elements 
present on the α1- α3 insert novel to PXR, including β1, β1’, and α2, are not present in 
the LXR LBD (Figure 3).  LXR’s ligand binding pocket is roughly half the size of PXR’s 
(650 Å3) and the observed binding of T1317 within the pocket uses essentially all the 
available space. The distinct and limited shape of the LXR pocket causes the T1317 
ligand to bind in a position rotated by ~30º and shifted by up to 5.3 Å relative to the 
position observed in the PXR complex. Sixteen LXR side chains contact T1317, two of 
which form hydrogen bonds with the ligand (His-435 and Thr-316).  His-435 in LXR 
corresponds in both sequence and structure to His-407 in PXR; however, Gln-285, which 
forms two polar contacts with T1317 in the PXR complex, is replaced by a leucine in 
LXR (Table II, Figure 4).  Thr-316, which forms the second polar interaction in LXR, is 
related in sequence to Phe-288 in PXR, but corresponds in structure to His-327, albeit 
shifted in position by ~5.5 Å.  The benzyl ring of T1317 forms aromatic contacts with 
phenylalanines 271 and 329 in LXR, which helps to position the ligand distinctly within 
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the pocket when compared to PXR.  It is also noted that distinct histidine-aromatic 
interactions are observed in PXR relative to LXR.  An edge-to-face aromatic interaction 
between His-435 and Trp-457 had been noted previously for LXR; this contact is 
replaced in PXR by a 3.8 Å edge-to-edge interaction between His-407 and Phe-429.  A 
second histidine aromatic contact is observed in PXR: a 3.3 Å face-to-edge interaction 
between Trp-299 and His-327 (Figure 4). In total, PXR and LXR share one conserved 
polar contact and eight conserved hydrophobic interactions in their respective complexes 
with T1317 (Table II).  In addition, both receptors directly contact corresponding residues 
located on the αAF helices of their AF-2 surfaces (Met-425 in PXR, Leu-453 in LXR).  
LXR apparently further stabilizes its AF-2 region by the formation of the aromatic 
contact between His-435 and Trp-457, which is located on αAF.  Taken together, these 
observations show that, in spite of differences in pocket shape and ligand orientation, 
numerous key contacts are conserved between these related receptors, leading to the 
efficient upregulation of targets genes by T1317. 
 
Design and Examination of Putative Antagonists.  Because T1317 appears to bind 
particularly strongly to PXR, we next sought to design a PXR antagonist using the T1317 
structure as a scaffold.  It is known that antagonists of other nuclear receptors (e.g., 
tamoxifen for the estrogen receptor) appear to function by sterically blocking the active 
position of αAF (28).  Thus, we chose to change the structure of the CF3-containing 
moiety in T1317, which binds adjacent to αAF in PXR (Figure 2).  Eleven analogues 
were synthesized that included both smaller and larger groups at this position (Figure 5; 
Scheme 1).  These compounds, along with T1317, were tested for their ability to bind to 
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PXR in an in vitro ligand-competition assay, and to activate PXR-mediated transcription 
in transient transfection assays in cultured cells (Table III).  Compounds 2-5, which 
retained the hydroxyl group and one CF3 group, all exhibited good binding to and 
activation of PXR.  In contrast, compounds 6 and 7, which retain the hydroxyl group but 
not a CF3, are poor binders and activators of PXR.  Similarly, compound 8, which 
contains a acetyl group, was the least efficacious compound examined.  These data 
support the importance of the hydrogen bond donated by the T1317 hydroxyl group to the 
His-407 side chain in PXR, in particular the electron withdrawing character of the CF3 
groups that polarize the hydroxyl group and improve its ability to share its hydrogen atom 
(25).   
 
Compounds 9-12 were designed to include large adducts adjacent to the hydroxyl and 
CF3 groups, with the goal of sterically disrupting αAF position.  We were surprised to 
find, however, that each compound bound well to PXR and served as an effective agonist 
rather than an antagonist (Table III).  For example, the presence of cyclohexyl or benzyl 
rings (compounds 9, 10) were apparently accommodated by the receptor’s ligand binding 
pocket.  Indeed, even a benzyl group contained on an extended and rigid two-methylene 
linker (compound 11) did not disrupt either ligand binding or receptor activation.  These 
observations suggest that the αAF and AF-2 region of PXR is reasonably conformable 
and capable of accommodating larger adducts than was previously appreciated.  The 
structural basis of these effects may be based on the mobile α2 region of PXR, which is 
present on a sequence insert unique to this receptor relative to other members of the 
nuclear receptor superfamily.  This stretch of the PXR LBD structure has been observed 
   139 
to shift in position by several Å between different ligand-bound complexes, and, in the 
case of the PXR structure bound to the large macrolide antibiotic rifampicin, to become 
completely disordered (12, 13, 14, 15).  The large adducts placed in the T1317 scaffold in 
compounds 9-12 may be directed toward this region of PXR and may create space for 
themselves by disrupting the position of α2 rather than αAF.  In addition, they could 
extend from the receptor’s pocket into solvent by creating a pore adjacent to Leu-240 
(Figure 2).  In either case, these observed effects underscore the fundamentally 
promiscuous nature of PXR in terms of ligand binding – the receptor contains a 
polypeptide insert that allows its binding pocket to expand and contract, facilitating the 
productive binding of a wide range of chemical structures. 
 
The activation of gene expression by T1317 analogues was also examined via LXRβ by 
transient transfection assays in cultured cells (Table III).  Similar to PXR, compounds 6-
8, which do not retain the hydroxyl-group proximal to a CF3 moiety, were poor ligands 
for LXR, highlighting the importance of the His-435 hydrogen received from the 
polarized ligand hydroxyl group.  In contrast to PXR, however, compounds 9 and 11 
were poor agonists of LXR, while compounds 10 and 12 were relatively effective.  
Considering the structure of the LXRβ-T1317 complex, the benzyl group in 10 may stack 
upon the aromatic Phe-268 side chain, an interaction not possible with compounds 9 or 
11.  For 12, the flexible nature of its CF3-rich extension may facilitate productive binding 
by protruding past Phe-268 into solvent.  Taken together, these observations regarding 
the impact of T1317 analogues on LXR-mediated gene expression reveal that this 
receptor, with its smaller ligand binding pocket and more narrow agonist profile, is more 
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accommodating to changes in chemical structure than was expected.  This highlights the 
plasticity present in the conserved nuclear receptor LBD fold, particularly for members of 
the former orphan class.
   141 
Discussion 
T1317 is an efficacious activator of gene transcription mediated by both the nuclear 
receptors PXR and LXRβ (19).  We show, by comparing the 2.8 Å resolution crystal 
structure of the PXR-T1317 complex to the LXRβ-T1317 complexes reported previously 
(22, 24, 25, 26), that these two LBDs share some analogous contacts to the ligand, but 
exhibit key differences as well.  The packing of aromatic side chains against the benzyl 
group of T1317, as well as the distinct placement of the proximal hydrogen-bonding 
residue Thr-316, cause the ligand to adopt a position in LXR rotated ~30º and shifted by 
~5 Å relative to that observed in PXR.  Still, nearly half the contacts between protein and 
ligand are conserved in both complexes, including the close hydrogen bond between a 
histidine side chain and a polarized hydroxyl group of the ligand.  Both LBDs also utilize 
an interaction between the same histidine side chain and an aromatic residue located on 
AF-helices of the receptors’ AF-2 regions: Trp-457 in LXR and Phe-429 in PXR.  
Indeed, it was noted in this PXR complex that the presence of the ligand appears to 
mediate the formation of a direct 3.8 Å aromatic contact between these side chains 
caused by their shift by 1 Å in position toward the bound T1317.  It is likely that the 
additional stabilization of the active conformation of αAF by this interaction plays in 
important role in the control of gene expression by both nuclear receptors. 
 
We were surprised both by the difficulty we experienced in designing an antagonist to 
either receptor, and by the plasticity the LXR receptor exhibits upon derivatization of the 
efficacious ligand T1317.  Given the numerous interactions observed between the T1317 
and the ligand binding pockets of both receptors, it was expected that adding bulky 
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groups to the region adjacent to the hydroxyl and dual CF3 moieties on the ligand would 
produce compounds that sterically block the active orientation of the AF-helix (as seen in 
the estrogen receptor with tamoxifen, for example) (28).  Instead, we found for PXR that 
compounds either bound and were agonists, or appeared incapable of binding to the 
receptor.  In addition, in the cases where reasonably large groups were added to the 
T1317 scaffold, the region of PXR’s ligand binding pocket adjacent to αAF was 
remarkably amenable to accommodating bulky additional atoms.  This is perhaps not 
surprising for PXR, given its well established promiscuous ligand binding character and 
the structural flexibility of unique regions (such as α2) in its ligand binding pocket.  It 
would appear that for PXR, in contrast to more rigid and specific steroid receptors like 
the estrogen receptor, ligands can bridge between rigid portions of the pocket, while more 
flexible regions of the protein can shift to accommodate a variety of distinct chemical 
structures. 
 
While the promiscuity of PXR is well known, we were not expecting to find that LXRβ 
would also show evidence for conformability in accommodating larger T1317 analogues.  
For example, compounds 10 and 12 were relatively effective agonists for LXR, in spite of 
the presence of large groups attached adjacent to T1317’s hydroxyl moiety (Figure 5).  
The structural basis of this is likely centered on the region around Phe-268 in the LXR 
pocket, which may stack with the aromatic group in 10 and provide a pore for the 
conformable group in 12. LXR did exhibit more specificity for the types of groups it can 
accommodate in this position relative to PXR, however, as non-aromatic or longer rigid 
adducts in 9 and 11, respectively, that still activated PXR were clearly not agonists for 
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LXRβ.  Thus, the ligand binding domains of numerous members of the nuclear receptor 
superfamily, particularly the former orphan receptors, are likely to posses some degree of 
structural flexibility to assist in the accommodation of chemically-distinct ligands.  It 
would appear that PXR, though, with its large and mobile α1-α3 insert, is at the extreme 
of this flexibility continuum with these unique features that are central to its significant 
promiscuity. 
 
We conclude that the unique aspects of the PXR ligand binding pocket may make 
antagonist design particularly difficult for this member of the nuclear receptor 
superfamily. It is noted that compounds 9 and 11 appear to be selective for PXR relative 
to LXRβ; as such, they may be useful as leads to address neurodegenerative diseases like 
Niemann-Pick C (8).  However, it may be necessary to look outside the ligand binding 
pocket of PXR to find sites effective at antagonizing the receptor using small molecules.  
Candidate sites on the LBD include the AF-2 surface (30) and the PXR homodimer 
interface, the disruption of which has been shown to impact productive coactivator 
binding by the receptor (16).  An effective PXR antagonist, if identified, may be of 
significant clinical use to reduce the activation of xenobiotic metabolism pathways during 
the therapeutic treatment of disease.
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Materials and Methods  
Protein Expression and Purification.  Generation of human PXR LBD in complex with 
the 88-amino acid fragment of human SRC-1 was accomplished as described previously 
(12, 13, 14, 15, 16). To prevent the formation of covalent complexes with reducing agent 
during crystallization, as has been seen with previous structures (data not shown), Cys-
284 within the ligand binding pocket of the human PXR LBD was replaced with serine. 
 
Crystallization. The human PXR ligand-binding domain/SRC-1 complex (hPXR-
LBD/SRC-1) was concentrated in the presence of 10-fold molar excesses T0901317 
(T1317; synthesized in-house) to a final concentration of 5 mg/mL. Crystallization was 
achieved by hanging-drop vapor diffusion against the following conditions at 22 oC: 50 
mM imidazole at pH 7.1, 10% 2-propanol, v/v. 
 
Data Collection and Structure Determination. The structure of the T1317-bound form of 
the ligand binding domain of human PXR was determined by molecular replacement 
using the crystal structure of the apo (unliganded) PXR as a search model (15).  Rotation 
and translation function searches were performed using AMoRe (32); clear solutions for 
each monomer of the dimer in the asymmetric unit were obtained in the proper space 
group, P212121. The structure was refined using CNS with the maximum likelihood 
function as a target, and included an overall anisotropic B-factor and a bulk solvent 
correction (33). Ten percent of the observed data were set aside for cross-validation using 
the free-R statistic prior to any structural refinement (34).  Manual adjustments and 
building of the model (including the placement of the T0901317 ligands and SRC-1 
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coactivator fragments) were performed using O (35) and σA-weighted electron density 
maps (36). The structure exhibits good geometry (Table I) with no Ramachandran 
outliers.  
 
Compound Syntheses. See Scheme 1 for steps involved in compound generation. 1H-
NMR spectra were recorded on a Varian Gemini 400 MHz NMR spectrometer. 1H-NMR 
spectra are reported as chemical shift δ, number of protons, multiplicity (s, singlet; d, 
doublet; t, triplet; m, multiplet; br s, broad singlet) and coupling constant (J) in Hertz. 
Electron Spray (ES) or Chemical Ionization (CI) was recorded on a Hewlett Packard 
5989A mass spectrometer. Mass spectrometry results are reported as the mass over 
charge. Purity by HPLC [Luna 20 x 4 mm 3.0 micron C18(2) column, water (+0.1% v/v 
formic acid)/MeOH (+0.075% v/v formic acid) gradient:  50% MeOH to 100 % MeOH 
for 5 minutes, holding at 100% MeOH for final 1 minute, flow rate = 2.0 mL/min]. 
Starting material are either available from commercial sources or via literature 
procedures. Abbreviations used in the examples below have their accepted meanings in 
the chemical literature. For example, DCM (dichloromethane), THF (tetrahydrofuran), 
MeCN (acetonitrile), DMSO (dimethylsulfoxide) and TBAF (tetrabutylammonium 
fluoride).  
Compound 6:  4-Aminobenzyl alcohol (10 g, 80 mmol) and benzenesulfonyl chloride 
(11.5 mL, 89 mmol) in pyridine were heated at 600C overnight.  Water was added and 
extracted with DCM.  The organic layer was separated and evaporated to dryness. The 
residue was purified by silica gel chromatography using ethyl acetate to give 17 g (80%) 
of intermediate sulfonamide:  1H-NMR (DMSO-d6) δ: 7.8 (s, 1H), 7.65 (m, 3H). 7.10 (d, 
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J=8.8Hz, 2H), 7.01 (d, J=8.8Hz, 2H), 5.04 (br s, 1H), 4.45 (s, 2H).  The intermediate 
sulfonamide (1.2 g, 4.6 mmol), 2,2,2-trifluoroethyltrifluoro-methane sulfonate (1.97 g, 
9.1 mmol) and K2CO3 (1.25 g, 9.1 mmol) in MeCN (20 mL) was heated at 800C 
overnight.  The solvents were removed under reduced pressure.  The residue was purified 
by silica gel chromatography using 50% ethyl acetate in hexanes to give  6 (1.0 g, 80%):   
1H-NMR (DMSO-d6) δ: 7.5-7.8 (m, 5H), 7.26 (d, J=8.5 Hz, 2H), 6.99 (d, J=8.5 Hz, 2H), 
5.30 (br s, 1H), 4.62 (m, 2H), 4.43 (s, 2H); LC/MS (ES+): m/e 346 (M+H), 100% purity. 
Compound 8:  Prepared in a similar fashion from 4-aminoacetophenone (5.0 g, 37.0 
mmol):  1H-NMR (DMSO-d6) δ: 7.90 (d, J=8.4 Hz, 2H), 7.56-7.71 (m, 5H), 7.27(d, J=8.4 
Hz, 2H), 4.64 (m, 2H), 2.48 (s, 3H), LC/MS (ES+) m/e 358 (M + H), 95% purity)  
Compound 2:  DMSO (5.5 mL, 28 mmol) was added dropwise to 2M oxalyl chloride in 
DCM (19 mL)at -780C under nitrogen followed by sequential addition of compound 6 
(10 g, 30 mmol) in DMSO:DCM (1:1) (20 mL) and neat triethylamine (75 mL). The 
reaction mixture was gradually warmed to room temperature overnight whereupon the 
solvents were removed under reduced pressure.  The residue was purified by silica gel 
chromatography with DCM to give an intermediate aldehyde (8.5 g, 85%):  1H-NMR 
(DMSO-d6) δ: 9.8 (s, 1H), 7.8 (m, 2 H), 7.52-7.81 (m, 5H), 7.38 (m, 2H). 
The intermediate aldehyde (5.0 g, 14.6 mmol) and trifluoromethyltrimethylsilane (2.5 g, 
17.5 mmol) in anhydrous THF (15 mL) was treated with a catalytic amount of TBAF at 
00C.  The reaction mixture was gradually warmed to room temperature overnight.  The 
reaction mixture was treated with 1N hydrochloric acid at room temperature for 1h. 
Water was added and extracted with DCM. The organic layer was separated and 
evaporated to dryness. The residue was purified by silica gel chromatography using 20% 
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ethyl acetate in hexanes to give 2 (5.0 g, 85%): 1H-NMR (MeOH-d4) δ: 7.65 (m, 1H), 
7.58 (d, J=8.6 Hz, 2 H), 7.52 (m, 2H), 7.45 (d, J=8.2 Hz, 2H), 7.11 (d, J=8.6 Hz, 2H), 
5.03 (m, 1H), 4.43 (m, 2H); LC/MS (ES+) m/e 414 (M+H), 96% purity. 
  
The following compounds were prepared in an analogous fashion: 
Compound 12: Treatment of intermediate aldehyde with heptafluoropropyl-
trimethylsilane (0.06 mL, 0.29 mmol) and purification by reverse phase chromatography 
on RP-C18 with 50-100% MeCN in water provided compound 12 (20 mg, 15%) as a 
racemic mixture:  1H-NMR (MeOH-d4) δ: 7.72 (m, 3H), 7.52 (m, 4H) 7.17 (d, J=8.6 Hz, 
2H), 4.41 (m, 2H), 2.22 (m, 1H), 1.99 (m, 1H), 1.38 (m, 2H), 0.91 (m, 3H); LC/MS 
(ES+) m/e 456 (M+H), 98% purity. 
 Compound 3:  Compound 3 was prepared in an analogous fashion from compound 8 to 
given 30 mg (25%) as a racemic mixture:  1H-NMR (MeOH-d4) δ: 7.49-7.65 (m, 7H), 
7.10 (d, J=8.6 Hz, 2H), 4.40 (m, 2H), 1.70(s, 3H), LC/MS (ES+) m/e 428 (M + H), 98% 
purity.  
Compound 4:  Compound 2 (2.5 g, 6.0 mmol), Dess-Martin periodinane (5.2 g, 12.0 
mmol) and pyridine (4mL, 48 mmol) in DCM (60 mL) was stirred at room temperature 
overnight.  The reaction was treated with 60 mL of an aqueous solution of 
NaHCO3:Na2S2O3 (5:1) and stirred at room temperature for 2 h. The organic layer was 
separated and evaporated to dryness. The residue was purified by silica gel 
chromatography using 50% ethyl acetate in hexanes to give an intermediate 
trifluoromethyl ketone (2.2 g, 90%):  1H-NMR (MeOH-d4) δ: 7.46-7.62 (m, 7H), 7.21 (d, 
J=8.6 Hz, 2H), 4.45 (m, 2H).  1M ethyl magnesium bromide in THF (0.5 mL) was slowly 
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added to a solution of the above ketone (100 mg, 0.24 mmol) in THF (3mL) at -780C. 
The reaction mixture was gradually warmed to room temperature overnight.  Saturated 
aqueous NH4Cl was added, and the aqueous layer was extracted with ethyl acetate. The 
organic layer was separated and evaporated to dryness. The residue was purified by 
reverse phase chromatography on RP-C18 using 50-100% MeCN in water to give 4 (5 
mg, 10%) as a racemic mixture: 1H-NMR (MeOH-d4) δ: 7.54-7.71 (m, 7H), 7.11 (d, 
J=8.6Hz, 2H), 4.45 (m, 2H), 2.21 (m, 1H), 1.98 (m, 1H), 0.87 (m, 3H); LC/MS (ES+) m/e 
445 (M+H), 98% purity. 
  
The following compounds were prepared in an analogous fashion from the above 
intermediate trifluoromethyl ketone: 
Compound 5:  Using 2M n-propyl magnesium bromide in diethyl ether followed by 
purification by reverse phase chromatography on RP-C18 with 50-100% MeCN in water 
gave rise to compound 5 (7 mg, 10%) as a racemic mixture:  1H-NMR (MeOH-d4) δ: 
7.47-7.65 (m, 7H), 7.11 (d, J=8.6 Hz, 2H), 4.41 (m, 2H), 2.22 (m, 1H), 1.99 (m, 1H), 
1.38 (m, 2H), 0.91 (m, 3H); LC/MS (ES+) m/e 456 (M+H), 95% purity.  
Compound 9:  Using 2M cyclohexyl magnesium bromide in diethyl ether (0.13 mL) 
followed by purification by reverse phase chromatography on RP-C18 with 50-100% 
MeCN in water provided compound 9 (20 mg, 20%) as a racemic mixture:  1H-NMR 
(MeOH-d4) δ: 7.43-7.89 (m, 7H), 7.11 (d, J=8.6 Hz, 2H), 4.41 (m, 2H), 2.61-2.05 (4m, 
5H), 1.03 (m, 3H), 0.93 (m, 3H); LC/MS (ES+) m/e 496 (M+H), 94% purity.  
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Compound 10:  Using 3M phenyl magnesium bromide in diethyl ether (0.09 mL) 
followed by purification via reverse phase chromatography on RP-C18 with 50-100% 
MeCN in water gave rise to compound 10 (70 mg, 70%) as a racemic mixture:  1H-NMR 
(MeOH-d4) δ: 7.33-7.69 (m, 12H), 7.11 (d, J=8.5 Hz, 2H), 4.42 (m, 2H), LC/MS (ES+) 
m/e 490 (M+H), 100% purity.  
Compound 11:  To a solution of phenylacetylene (83 mg, 0.75 mmol) in THF (2 mL) 
was added 1.6M n-BuLi in hexanes (0.315 mL, 0.5 mmol) at -780C over 30 minutes.  
After this time, a solution of the above intermediate trifluoromethylketone (100 mg, 0.25 
mmol) in THF (2 mL) was added. The reaction mixture was gradually warmed to room 
temperature overnight.  Saturated aqueous NH4Cl was added, and the aqueous layer was 
extracted with DCM. The organic layer was separated and evaporated to dryness. The 
residue was purified by reverse phase chromatography on RP-C18 using 50-100% MeCN 
in water to give compound 11 (77 mg, 75%) as a racemic mixture:  1H-NMR (MeOH-
d4) δ: 7.43-7.80 (m, 12H), 7.17 (d, J=8.6 Hz, 2H), 4.42 (m, 2H); LC/MS (ES+) m/e 514 
(M + H), 98% purity.  
Compound 7:  Compound 7 was prepared from 8 (100 mg, 0.28 mmol) and 1M vinyl 
magnesium bromide (0.84mL, 0.84 mmol) using the procedure described for the 
preparation of 4.  Purification by reverse phase chromatography on RP-C18 using 50-
100% MeCN in water provided 7 (30 mg, 30%) as a racemic mixture: 1H-NMR (MeOH-
d4) δ: 7.49-7.67 (m, 5H), 7.32 (d, J=8.4 Hz, 2H), 7.03 (d, J=8.4 Hz, 2H),  4.79 (m, 1H), 
4.39 (m, 2H), 1.40(s,2H); LC/MS (ES+) m/e 358 (M +H), 98% purity.  
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Transient Transfections. Transient transfection and reporter gene assays using full-length 
human PXR and LXRβ were performed as described previously (12). 
 
Competition Ligand Binding Assay. Competitive ligand binding assays using [N-methyl-
3H]-GW0438X were preformed as described elsewhere (16). 
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 Table I.  Crystallographic Statistics for the PXR-T0901317 Complex 
 
 
Resolution (Å; highest shell) 50-2.8 Å (2.9-2.8) 
Space Group P212121 
Asymmetric Unit two molecules 
Cell Constants (Å, °) 
 
 
 
Data Collection Facility 
a = 83.9 b = 90.6 
c = 105.7 
α =  β = γ = 90 
 
SER-CAT (APS) 
Total Reflections 
Unique Reflections 
119,110 
20,332 
Mean Redundancy (highest shell) 5.8 (5.4) 
Rsym∗ (%; highest shell) 13.5 (46.7) 
Completeness (%; highest shell) 
Mean I/σ (highest shell) 
97.6 (91.1) 
25.9 (5.1) 
  
Rcryst† 21.6 
Rfree‡ 27.9 
                                                 
∗
 Rsym = Σ|I-<I>| / ΣI, where I is the observed intensity and <I> is the average intensity of multiple 
symmetry-related observations of that reflection.  
†
 Rcryst = Σ||Fobs|-|Fcalc|| / Σ|Fobs|, where Fobs and Fcalc are the observed and calculated structure factors, 
respectively. 
‡
 Rfree = Σ||Fobs|-|Fcalc|| / Σ|Fobs| for 10% of the data not used at any stage of structural refinement. 
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Table II.  Comparison of Residues Contacting T0901317 in PXR and LXR.  Amino 
acids forming hydrogen bonding interactions with ligand are listed in bold, those on the 
terminal αAF helices of the receptors are underlined, and those not contacting ligand are 
in italics and parentheses. 
 
 
PXR LXR 
Gln-285 Leu-313 
His-327 (Ser-357) 
His-407 His-435 
Leu-209 --* 
Val-211 --* 
Leu-240 Phe-268 
Met-243 Phe-271 
Met-246 Leu-274 
Phe-288 Thr-316 
Trp-299 Ile-327 
Tyr-306 (Tyr-335) 
Leu-411 Val-439 
Ile-413 Leu-442 
Phe-420 Leu-449 
Met-425 Leu-453 
(Cys-284-Ser)† Met-312 
(Cys-301)‡ Phe-329 
(Leu-206) Leu-345 
(Met-323) Ile-353 
(Phe-429) Trp-457 
 
 
 
* Residues 209 and 211 are on a sequence insert novel to PXR; thus, no equivalent 
side chains exist in LXR. 
 
† Cys-284 was mutated to serine to improve the crystallization behavior of PXR; 
see Materials and Methods. 
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‡ While Cys-301 corresponds in sequence to Phe-329, the PXR side chain Phe-288 
overlaps structurally with this LXR phenylalanine; see Figure 4. 
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Table III.  T0901317 Analogues and Their Impact on Human PXR and LXRβ.  See 
Figure 5 for analogue structures.  Compound 1 is T0901317 present in the PXR complex 
structure presented here. 
 
 
Compound PXR pIC50 PXR pEC50 PXR %max LXR pEC50 LXR %max 
1 7.4 7.9 93 7.0 100 
2 5.0 6.0 90 <4.5 19 
3 5.4 6.3 104 5.8 50 
4 6.6 6.9 101 5.4 73 
5 6.5 6.8 96 5.6 27 
6 5.1 5.0 23 <4.5 3 
7 5.6 5.0 45 <4.5 3 
8 5.8 5.0 11 <4.5 3 
9 7.6 8.5 103 <4.5 9 
10 7.2 7.8 99 5.5 30 
11 6.2 6.0 139 <4.5 5 
12 7.7 8.0 98 6.2 58 
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Figure Legends 
Figure 1.  Crystal structure of the homodimer in the asymmetric unit of the ligand 
binding domain of human PXR (PXR LBD) in complex with T0901317 (T1317).  The 
PXR LBD in one monomer is rendered in red, yellow and green, and in the other 
monomer in cyan, magenta and pink.  The fragments of the steroid receptor coactivator 1 
(SRC-1) are shown in aqua and orange, and the T1317 ligands in magenta and green. 
 
Figure 2.  Stereoview of the binding of T0901317 within the ligand binding pocket of the 
human PXR LBD.  Residues making polar contacts are rendered in green, those making 
hydrophobic interactions are in red, with Met-425 from αAF highlighted in yellow. 
 
Figure 3.  Superposition of the human PXR LBD monomer (red) on that of the human 
LXRβ LBD (gold), with the T0901317 ligands present in both structures shown in 
magenta for PXR and blue for LXR. 
 
Figure 4.  Stereoview comparing the binding of T0901317 to the LBDs of human PXR 
and LXRβ.  Human PXR residues and T1317 ligand are colored as in Figure 1B, except 
Phe-429 and Met-243, which are shown in white.  In LXR, residues forming polar ligand 
contacts are shown in cyan, while those forming hydrophobic interactions are in gold or, 
for Leu-452 and Tyr-335, in pink. 
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Figure 5.  Structures of analogues of T0901317 (compound 1) examined for their impact 
on human PXR and human LXRβ. 
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Figure 1.   
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Scheme 1. 
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8
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d or h
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7: R = H 
 
 
 
Reaction conditions: (a) benzenesulfonyl chloride, pyridine, 60oC; (b) 2,2,2-trifluoroethyl 
trifluoromethylsulfonate, K2CO3, MeCN, 800C; (c) oxalyl chloride, DMSO, Et3N, rt; (d) 
trifluoromethyltrimethylsilane, TBAF, THF, 500C; (e) Dess-Martin periodinane, pyridine, 
DCM, rt; (f) RMgBr, THF, -780C to rt; (g) phenylacetylene, n-BuLi, THF, -780C to rt; (h) 
vinylmagnesiun bromide, THF, -780C to rt. 
 
 
   163 
References 
 
1. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-
Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. (1998) 
Proc Natl Acad Sci U S A  95, 12208-13. 
 
2. Blumberg, B.; Sabbagh, W., Jr.; Juguilon, H.; Bolado, J., Jr.; van Meter, C. M.; 
Ong, E. S.; Evans, R. M. (1998) Genes & Develop  12, 3195-205. 
 
3. Kliewer, S. A.; Moore, J. T.; Wade, L.; Staudinger, J. L.; Watson, M. A.; Jones, 
S. A.; McKee, D. D.; Oliver, B. B.; Willson, T. M.; Zetterstrom, R. H.; Perlmann, 
T.; Lehmann, J. (1998) M. Cell  92, 73-82. 
 
4. Carnahan, V. E.; Redinbo, M. R. (2005) Curr Drug Metab 6, 357-67. 
 
5. Lehmann, J. M.; McKee, D. D.; Watson, M. A.; Willson, T. M.; Moore, J. T.; 
Kliewer, S. A. (1998) J Clin Invest  102, 1016-23. 
 
6. Moore, J. T.; Kliewer, S. A. (2000) Toxicology 153, 1-10. 
 
7. Moore, L. B.; Goodwin, B.; Jones, S. A.; Wisely, G. B.; Serabjit-Singh, C. J.; 
Willson, T. M.; Collins, J. L.; Kliewer, S. A. (2000) Proc Natl Acad Sci U S A  
97, 7500-2. 
 
8. Langmade, S. J.; Gale, S. E.; Frolov, A.; Mohri, I.; Suzuki, K.; Mellon, S. H.; 
Walkley, S. U.; Covey, D. F.; Schaffer, J. E.; Ory, D. S. (2006) Proc Natl Acad 
Sci U S A  103, 13807-12. 
 
9. Orans, J.; Teotico, D. G.; Redinbo, M. R. (2005) Mol Endocrinol  19, 2891-900. 
 
10. Ingraham, H. A.; Redinbo, M. R. (2005) Curr Opin Struct Biol  15, 708-15. 
 
11. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, 
R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. (1998) Nature 
395, 137-43. 
 
12. Chrencik, J. E.; Orans, J.; Moore, L. B.; Xue, Y.; Peng, L.; Collins, J. L.; Wisely, 
G. B.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R. (2005) Mol Endocrinol  
19, 1125-34. 
 
13. Watkins, R. E.; Davis-Searles, P. R.; Lambert, M. H.; Redinbo, M. R. (2003) J 
Mol Biol  331, 815-28. 
 
14. Watkins, R. E.; Maglich, J. M.; Moore, L. B.; Wisely, G. B.; Noble, S. M.; Davis-
Searles, P. R.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R. (2003) 
Biochemistry  42, 1430-8. 
   164 
 
15. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; 
Williams, S. P.; Willson, T. M.; Kliewer, S. A.; Redinbo, M. R. (2001) Science  
292, 2329-33. 
 
16. Noble, S. M.; Carnahan, V. E.; Moore, L. B.; Luntz, T.; Wang, H.; Ittoop, O. R.; 
Stimmel, J. B.; Davis-Searles, P. R.; Watkins, R. E.; Wisely, G. B.; Lecluyse, E.; 
Tripathy, A.; McDonnell, D. P.; Redinbo, M. R. (2006) Biochemistry  45, 8579-
8589. 
 
17. Janowski, B. A.; Willy, P. J.; Devi, T. R.; Falck, J. R.; Mangelsdorf, D. J. (1996) 
Nature  383, 728-31. 
 
18. Kalaany, N. Y.; Gauthier, K. C.; Zavacki, A. M.; Mammen, P. P.; Kitazume, T.; 
Peterson, J. A.; Horton, J. D.; Garry, D. J.; Bianco, A. C.; Mangelsdorf, D. J. 
(2005) Cell Metab  1, 231-44. 
 
19. Laffitte, B. A.; Repa, J. J.; Joseph, S. B.; Wilpitz, D. C.; Kast, H. R.; 
Mangelsdorf, D. J.; Tontonoz, P. (2001) Proc Natl Acad Sci U S A  98, 507-12. 
 
20. Peet, D. J.; Turley, S. D.; Ma, W.; Janowski, B. A.; Lobaccaro, J. M.; Hammer, R. 
E.; Mangelsdorf, D. J. (1998) Cell 93, 693-704. 
 
21. Zhang, Y.; Repa, J. J.; Gauthier, K.; Mangelsdorf, D. J. (2001) J Biol Chem  276, 
43018-24. 
 
22. Hoerer, S.; Schmid, A.; Heckel, A.; Budzinski, R. M.; Nar, H. (2003) J Mol Biol  
334, 853-61. 
 
23. Jaye, M. C.; Krawiec, J. A.; Campobasso, N.; Smallwood, A.; Qiu, C.; Lu, Q.; 
Kerrigan, J. J.; De Los Frailes Alvaro, M.; Laffitte, B.; Liu, W. S.; Marino, J. P., 
Jr.; Meyer, C. R.; Nichols, J. A.; Parks, D. J.; Perez, P.; Sarov-Blat, L.; 
Seepersaud, S. D.; Steplewski, K. M.; Thompson, S. K.; Wang, P.; Watson, M. 
A.; Webb, C. L.; Haigh, D.; Caravella, J. A.; Macphee, C. H.; Willson, T. M.; 
Collins, J. L. (2005) J Med Chem 48, 5419-22. 
 
24. Svensson, S.; Ostberg, T.; Jacobsson, M.; Norstrom, C.; Stefansson, K.; Hallen, 
D.; Johansson, I. C.; Zachrisson, K.; Ogg, D.; Jendeberg, L. (2003) EMBO J  22, 
4625-33. 
 
25. Williams, S.; Bledsoe, R. K.; Collins, J. L.; Boggs, S.; Lambert, M. H.; Miller, A. 
B.; Moore, J.; McKee, D. D.; Moore, L.; Nichols, J.; Parks, D.; Watson, M.; 
Wisely, B.; Willson, T. M. (2003) J Biol Chem 278, 27138-43. 
 
26. Farnegardh, M.; Bonn, T.; Sun, S.; Ljunggren, J.; Ahola, H.; Wilhelmsson, A.; 
Gustafsson, J. A.; Carlquist, M. (2003) J Biol Chem  278, 38821-8. 
   165 
 
27. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, 
J. E.; McKee, D. D.; Galardi, C. M.; Plunket, K. D.; Nolte, R. T.; Parks, D. J.; 
Moore, J. T.; Kliewer, S. A.; Willson, T. M.; Stimmel, J. B. (2002)Nature  415, 
813-7. 
 
28. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; 
Greene, G. L. (1998) Cell  95, 927-937. 
 
29. Synold, T. W.; Dussault, I.; Forman, B. M. (2001) Nat Med 7, 584-90. 
 
30. Huang, H.; Wang, H.; Sinz, M.; Zoeckler, M.; Staudinger, J.; Redinbo, M. R.; 
Teotico, D. G.; Locker, J.; Kalpana, G. V.; Mani, S. (2006) Oncogene  in press. 
 
31. Takeshita, A.; Taguchi, M.; Koibuchi, N.; Ozawa, Y. (2002) J Biol Chem  277, 
32453-8. 
 
32. Navaza, J.; Saludjian, P. (1997) Methods Enz. 276A, 581-594. 
 
33. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-
Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. 
J.; Rice, L. M.; Simonson, T.; Warren, G. L. (1998) Acta Crystallogr, D  54, 905-
21. 
 
34. Brünger, A. T. (1993) Acta Crystallogr. D Biol. Crystallogr. 49, 24-36. 
 
35. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. (1991) Acta Crystallogr. A  
47, 110-119. 
 
36. Read, R. J. (1986) Acta Crystallogr. A  42, (140-149). 
 
